

Note: Page numbers followed by *f* refer to figures; those followed by *t* refer to tables; those followed by *b* refer to boxes.

- %FE_{Na} test, 220
- (1,3)- β -D-glucan assay, detection of yeasts by, 459
- 4K score, definition of, 647
- 4Ts score, probability of heparin-induced thrombocytopenia, 382
- 5'-nucleotidase, definition and normal range of, 320*t*, 321
- 5 α -reductase enzymes, types of, 626
- 6MWT. *See* Six-minute walk test
- A**
- α -fetoprotein (AFP)
 - definition and normal range of, 520
 - use of tumor marker, 516*t*
- A1c. *See* Glycosylated hemoglobin
- ABCB1* gene, 389
- Abdominal pain, acid-base disorder with, 295*b*
- ABG. *See* Arterial blood gases
- Absorbance optical system, 29
- Absorption transition vector, 22
- ABW. *See* Average body weight
- ACC. *See* American College of Cardiology
- Accuracy
 - CLIA-waived POC tests variables that affect, 53
 - definition and calculation of, 3
 - laboratory request form needs completeness and, 77
 - qualitative CLIA-waived POC test and definition of, 53
- Acetaminophen
 - delay in toxicity symptoms with, 554
 - hepatotoxicity after overdose of, 554*f*
 - poisoning from multiple-ingredient drugs containing, 548*b*
 - Rumack-Matthew nomogram for, 554
 - therapeutic range, clinical considerations, sample timing, 90
 - See also* Serum acetaminophen
- ACI. *See* Acute kidney injury
- Acid, definition of, 287
- Acid-base chemistry, 287
- Acid-base disorders
 - classifications of, 291, 292*t*
 - types and causes of, 292–294
- Acid-base homeostasis, 239–240, 290–291
- Acid-base physiology, 290
- Acidemia, definition of, 287
- Acid-fast bacilli (AFB), timing of lab test for, 11
- Acid-fast stain, for *Mycobacterium*, 4
- Acidosis, definition of, 287
- ACPA. *See* Anticitrullinated protein antibodies
- Acquired immunodeficiency syndrome (AIDS), HIV as cause of, 474
- ACR. *See* Albumin-to-creatinine ratio
- ACS. *See* Acute coronary syndrome
- ACT. *See* Activated clotting time
- ACTH. *See* Adrenocorticotrophic hormone
- Activated clotting time (ACT)
 - definition and normal range, 390
 - monitor anticoagulation therapy with, 385
- Activated partial thromboplastin time (aPTT)
 - causes of decreased level of, 390
 - causes of prolonged, 389
 - definition and normal range, 389
 - effect of warfarin on, 390
 - monitor anticoagulation therapy with, 385, 389–390
- Activated protein C (APC), factor V Leiden mutation and, 386, 387
- Acute coronary syndrome (ACS), 139, 141*b*, 142*b*
- Acute dyspnea, BNP levels in, 144*t*
- Acute kidney injury (AKI), 203
- Acute-phase reactants, definition and diseases associated with, 498, 503, 504–505
- ADA. *See* American Diabetes Association
- ADAM. *See* Androgen deficiency in aging men
- Addison disease, cause and symptoms of, 188
- ADH. *See* Antidiuretic hormone
- Adnexal tumor, hirsutism secondary to, 612*b*
- Adolescent, definition of age group, 574*t*
- Adrenal disorders, 186–188
- Adrenal gland, anatomy and physiology, hormone production of, 186, 625
- Adrenal insufficiency, cause and symptoms of, 188
- Adrenocorticotrophic hormone (ACTH)
 - pregnancy affects, 13
 - test adrenal insufficiency with, 188
 - timing of lab test for, 11
- Adult, definition of age group, 574*t*
- AEDs. *See* Antiepileptic drugs
- AFB. *See* Acid-fast bacilli
- Affinity separation method, description/ advantage of HgbA1c test using, 57
- AFP. *See* α -fetoprotein
- AG. *See* Anion gap
- Agar, bacterial growth medium and types of, 407*t*
- Agar dilution susceptibility testing, procedure for, 415
- Age
 - laboratory test results affected patient's, 11
 - number/affinities of drug receptors change with, 81
- Age groups, definitions and terminology used for, 574*t*
- Agglutination immunoassay, description and use of, 32, 32*f*
- Agglutination reaction, types of, 32
- Aging
 - laboratory test results affected by, 12*t*
 - physiologic changes associated with, 11
- Aging Male's Symptoms (AMS) scale, 628
- Agranulocytosis, 372
- AHA. *See* American Heart Association
- AHFS Drug Information*, description of, 47
- AIDS. *See* Acquired immunodeficiency syndrome
- Alanine aminotransferase (ALT, SGPT)
 - definition and normal range of, 316, 324–325
 - pediatric and adult normal ranges, 592
- Albumin
 - description and normal range of, 317
 - prolonged INR and low serum, 333*b*
 - See also* Serum albumin
- Albumin-to-creatinine ratio (ACR), kidney function and, 202
- Albuminuria, ADA recommendations for, 176–177
- ALK. *See* Anaplastic lymphoma kinase
- Alkalemia, definition of, 287
- Alkaline phosphatase (ALP)
 - definition and normal range of, 316, 320, 320*t*, 321*t*
 - pediatric and adult normal ranges, 592
- Alkalosis, definition of, 287
- Allele
 - definition of, 120*t*
 - no-function, 124
- Allele function, standardized by CPIC, 123
- ALP. *See* Alkaline phosphatase
- ALT. *See* Alanine aminotransferase
- Altitude, lab tests affected by, 13–14

- AMA. *See* Antimitochondrial antibodies
- Amenorrhea
 definition, causes, symptoms of, 605–607, 606*t*, 607*t*
 exercise and weight loss as cause of, 608*b*
 laboratory tests and diagnosis of, 608*t*
- American College of Cardiology (ACC)
 ASCVD prevention guidelines of, 59
 dyslipidemia guidelines, 153
- American College of Emergency Physicians, 546
- American College of Rheumatology (ACR), 501
- American Diabetes Association (ADA)
 recommends diabetes tests be NGSP certified, 57
 screening schedule for high-risk persons, 169
- American Heart Association (AHA)
 ASCVD prevention guidelines of, 59
 cholesterol guidelines by, 149
 dyslipidemia guidelines, 153
- American Society of Andrology, 629
- American Thoracic Society (ATS), 307
- American Urological Association Symptom Index (AUA-SI), 636–637
- American Urological Association/Society of Urologic Oncology, 5*b*
- Aminoglycosides
 importance of sample timing with, 87
 therapeutic range for, 96–97
- Aminotransferases, types of, 316, 324–325
- Amiodarone, therapeutic range and clinical considerations, 103
- Ammonia, definition, normal range, causes of increased, 325–326
- AmpC, bacterial hyperproduction of, 418
- Amperometry, description of, 170
- Amphetamine abuse, reliability of amphetamine results to show, 547*b*
- AMS. *See* Aging Male's Symptoms
- Amylase, description and normal range of blood and urine, 339–340
- ANA. *See* Antinuclear antibodies
- Anaerobic bacteria, tests to identify, 420–421
- Analyte, definition, reference ranges vary for different forms, 3
- Analyzers, components/functions of automated, 20
- Anaplastic lymphoma kinase (ALK)
 description of fusion gene, 523
 personalized cancer treatment with tumor marker, 516*t*
- ANCA. *See* Antineutrophil cytoplasmic antibodies
- Androgen deficiency in aging men (ADAM), definition, causes of, questionnaire for, 626, 628
- Andropause, definition of, 626
- Anemia
 acute blood loss and, 365–366
 chronic diseases that cause, 367
 definition and causes of, 5, 359
 identifying candidates for CLIA-waived POC test, 58
 increased mean cell volume with, 361–362*b*
 iron stores and, 364*b*
 low platelet count and, 366*b*
 pediatric causes of, 595
 types and diagnosis of, 360*f*, 360*t*
- ANF. *See* Atrial natriuretic factor
- Angiotensin receptor neprilysin inhibitor (ARNI), 145
- Anion gap (AG)
 definition and normal range of, 289
 causes of, 289, 292, 293*t*
- Anode stripping voltammetry, 26
- Antagonism, definition of, 417
- Antibiogram
 choosing antibiotic therapy using a cumulative, 431*b*
 CLSI recommendations for developing, 430*t*
 hospital, 428, 429, 430*f*
- Antibiotic activity, dilution methods to measure, against particular bacterium, 412
- Antibiotic concentration gradient methods, 416
- Antibiotic resistance mechanisms, methods of detecting, 418
- Antibody
 agglutination reaction, avidity and affinity of, 32
 structure of an, 492*f*
- Antibody tests, detect pathogens and infection, 55
- Anticitrullinated protein antibodies (ACPA)
 description of, 493
 JIA and presence of, 504
 quantitative and qualitative assay of, 493
 in rheumatoid arthritis, 502
- Anticoagulant drug therapy, coagulation tests to monitor, 381*t*
- Anticoagulant medications, action of, 380*t*
- Antidiuretic hormone (ADH)
 diabetes insipidus and, 188–189
 water/sodium regulation by, 231, 232
- Anti-double-stranded DNA (anti-dsDNA) test, SLE and presence of, 505
- Antidoping, control of doping by, 558
- Antiepileptic drugs (AEDs)
 applications and indications for monitoring, 82*t*, 91–96
 CYP3A5 gene and, 125
 interpreting drug concentrations of, 82*t*
 trough level used as therapeutic confirmation for, 86
 unbound serum concentration of, 89*b*
- Antifungal drugs
 applications and therapeutic range for, 84*t*, 99–100
 interpreting drug concentrations of, 84*t*
- Antifungal susceptibility testing, 461
- Antigen, definition of, 491
- Antigen-detection test, molecular CLIA-waived POC test higher sensitivity than, 66
- Antigen tests
 CLIA-waived POC test for influenza A and B, 63–64, 65*t*
 description and advantages/disadvantages of, 55
 detect pathogens and infection with, 55
- Anti-histone (nucleosome) antibodies, definition and normal range of, 495
- Antikinetochore antibody, test for, 495
- Anti-La/SSB antibodies, SLE and presence of, 505
- Antimicrobial drugs
 applications for, 96–99
 interpreting drug concentrations of, 83*t*
- Antimicrobial combination test (synergy test), description of, 417
- Antimicrobial susceptibility tests
 advantages and disadvantages of, 413*t*
 quantitative/qualitative methods for, 411–412, 412*t*
- Antimicrobial therapy, benefits of combination, 417
- Antimitochondrial antibodies (AMA), 331
- Antimycobacterial drugs, for tuberculosis, 100
- Antineutrophil cytoplasmic antibodies (ANCA), definition of, 496–497
- Antinuclear antibodies (ANA)
 definition of, 493–494
 drugs that affect test for, 13
 JIA and presence of, 504
 SLE and presence of, 505
 test for rheumatoid arthritis, 502–503
 titer for, 496
- Antinuclear cytoplasmic antibodies, rheumatic disease and, 497*t*
- Antiphospholipid antibody syndrome (APS), 386, 506
- Antiretroviral drugs, applications, therapeutic range, clinical considerations, 100–101
- Antiretroviral drug resistance, phenotypic and genotypic assays for, 480–481
- Anti-Ro/SSA antibodies, SLE and presence of, 505
- Anti-Sm antibodies, SLE and presence of, 505
- Antithrombin (AT), coagulation inhibited by, 379

- Antithrombotic medications, action of, 380*t*
- Antithyroid antibodies, diseases with high level of, 186
- Antitopoisomerase I antibody, test for, 495
- Antiviral susceptibility testing, description of, 474
- Anti-Xa, definition, use, and normal range of, 391
- APC. *See* Activated protein C
- Apolipoproteins, function of, 150, 150*f*
- Apparent strong ion difference (aSID), 290
- APS. *See* Antiphospholipid antibody syndrome
- aPTT. *See* Activated partial thromboplastin time
- Area under the curve (AUC), steady-state average concentration and, 87
- ARNI. *See* Angiotensin receptor neprilysin inhibitor
- Array-based comparative hybridization, definition of, 40
- Arrhythmia, definition of, 139
- Arterial bicarbonate, definition and normal range of, 288–298
- Arterial blood gas (ABG)
interpretation of, 291
steps for assessment of, 291–292
definition and use of, 287–289
- Arterial oxygen content (CaO₂), 289
- Arterial oxygen saturation (SaO₂), definition and normal range of, 289
- Arterial partial pressure of carbon dioxide (PaCO₂), definition and normal range of, 288
- Arterial partial pressure of oxygen (PaO₂), normal range and factors that affect, 288
- Arterial pH, definition and normal range of, 288
- Arthritis, differential diagnosis for, 504*b*
- ASCVD. *See* Atherosclerotic cardiovascular disease
- aSID. *See* Apparent strong ion difference
- Aspartate aminotransferase (AST, SGOT)
definition and normal range of, 316, 324–325
pediatric and adult normal ranges, 592
- Assay
digoxin, 6
total bound and unbound substance measured by, 3
See also Specific names of assays
- Association for Molecular Pathology PGx Working Group, 123
- Association for Molecular Pathology, 124
- AST. *See* Aspartate aminotransferase
- Asthma, spirometry to diagnose, 304, 305*b*
- Atherosclerotic cardiovascular disease (ASCVD)
community/corporate health programs screen for, 58
risk factors for, 149
U.S. deaths due to, 58
- Atomic absorption (AA) spectrophotometer, uses for, 22–23
- Atomic emission spectrophotometer, 22
- Atoms, clinical laboratory use and classes of, 32
- Atrial natriuretic factor (ANF), 233
- Atrial natriuretic hormone, pregnancy affects, 13
- AUA-SI. *See* American Urological Association Symptom Index
- AUC. *See* Area under the curve
- Autoantibody testing, for diabetes mellitus, 167
- Autoinduction, example of, 85–86
- Automation, definition and characteristics of lab test, 19–20
- Automation, hospital/clinical laboratory, 20–21
- Average body weight (ABW), creatinine clearance and, 206
- Azotemia, causes of, 204*t*
- ## B
- B lymphocytes, types and functions of, 372
- β-ketone test, ketones in blood, 175
- β-lactam drugs, therapeutic range and clinical considerations, 98–99
- β-lactamase activity, antibiotic resistance and detection of, 418
- β-thromboglobulin, definition and normal range of, 385
- β-trace protein (BTP), description and normal range for, 203
- β₂, β-2 microglobulin (B₂M, B2M)
definition and normal range of, 520
description and normal range for, 203
use as tumor marker, 516*t*
- B₂M, B2M. *See* β-2 microglobulin
- Back-extrapolated volume (BEV), 307
- Bacteria
biochemical tests and rapid diagnostic tests to detect, 407–408
characteristics of, 403
culture and identification of, 406
genotypic and phenotypic testing of, 406–407
growth requirements for aerobic and anaerobic, 406
laboratory tests for detecting miscellaneous, 422–427*t*, 428*f*
specimen collection and identification of, 403–404
- Bacterial meningitis, laboratory tests to diagnose, 431–433, 432*t*
- Bacterial pneumonia, laboratory tests to diagnose, 433–434
- Bacteriuria, definition of, 213
- BAMT. *See* Blood assay for *Mycobacterium tuberculosis*
- Bariatric surgery, copper deficiency after, 255
- Baroreceptors, function of, 231
- Basal body temperature (BBT), infertility and charting of, 613
- Base, definition of a, 287
- Baseline laboratory tests, obtained prior to therapy, 15
- Basic metabolic panel (BMP), example of lab test profile, 8
- Basophils, definition, function, and normal range of, 369
- Bayesian method, dosage adjustment method, 88, 97, 98
- BBT. *See* Basal body temperature
- BCR-ABL fusion gene, Philadelphia chromosome and, 521
- BCT. *See* Bronchial challenge test
- Benign prostatic hyperplasia (BPH), definition, symptoms, and causes, 636
- BEV. *See* Back-extrapolated volume
- Bias, quantitative CLIA-waived POC test and definition of, 53
- Bicarbonate (HCO₃⁻), 288
- Bicarbonate/carbonic acid system, extracellular buffer, 290
- Bilirubin
conjugated versus unconjugated subforms versus bound to albumin, 3–4
definition, production, and normal range of, 321, 322*f*
description and normal range for urine, 217
direct versus indirect, 4
pediatric and adult normal ranges, 593
See also Total bilirubin
- Bioavailability, grapefruit juice enzyme and drug, 13
- Bioavailable testosterone
laboratory tests for, 631
pediatric and adult normal range, 630, 630*t*
- Bioelectrical impedance analysis, to evaluate malnutrition, 281
- Biologic rhythms, characteristics and types of, 12
- Biologic specimens, types of, 404*t*
- Biological marker. *See* Biomarker
- Biological rhythm. *See* Biologic rhythm
- Biomarker, FDA definition of, 4
- Biotin nutritional supplement, elevated thyroid hormones caused by, 46*b*
- Bladder urothelial carcinoma recurrence surveillance, 5*b*
- Bleeding disorders, coagulation tests to diagnose, 386
- Bleeding time (BT), definition and normal range of, 385

- Blood
- components of whole, 7
 - description and normal range for urine, 217
 - laboratory tests for HIV for screening donor, 475*t*
- Blood assay for *Mycobacterium tuberculosis* (BAMT), 485
- Blood chemistries
- CLIA-waived POC tests for, 59
 - identifying patients for CLIA-waived POC tests, 59
 - pharmacist monitors renal/liver function by, 59
- Blood chemistry analyzer, types of analytes measured by, 59
- Blood coagulation, screening test for, 8
- Blood culture, example of diagnostic test, 8
- Blood ethanol, toxic effects and medicolegal problems from, 553, 553*t*
- Blood sampling, methods, sites, and volume for pediatric patients, 574–575
- Blood urea nitrogen (BUN)
- causes of elevated, 204, 204*t*
 - description and normal range for, 204
 - example of lab test profile, 8
 - relationship to serum creatinine SCr, 204–205, 206*f*
 - causes of deceased, 204
- Blood urea nitrogen:serum creatinine ratio (BUN:SCr), description, normal range, 236–237
- Blood volume, age group and total, 575*t*
- BMI. *See* Body mass index
- BMP. *See* Basic metabolic panel
- BNP. *See* B-type natriuretic peptide; Brain natriuretic peptide
- Body mass index (BMI), 144
- Body plethysmography, definition and use of, 309
- Body sites
- examples of normally sterile, 408*t*
 - normal colonizing bacteria flora in, 409*t*
- Body surface area (BSA)
- Dubois-Dubois and Mostellar equations for, 206
 - pediatric patients and estimating, 589
- Bone marrow, description and physiology of, 355
- Bone marrow biopsy, reason for and sites of, 356–357
- Bone marrow suppressant drugs, lab tests affected by, 13
- Bound substance, effect of unbound substance versus, 3
- Boyle's law, 309–310
- BPH. *See* Benign prostatic hyperplasia
- BPH Impact Index score, 637
- BRAF
- description of viral oncogene, 522–523
 - personalized cancer treatment with tumor maker, 516*t*
- Brain natriuretic peptide (BNP), 233–234
- Branched DNA amplification, 38
- Breast cancer, use of tumor markers in, 518*b*
- Breath alcohol test, 553–554
- Brief Male Sexual Function Inventory, 634, 634*t*
- Bronchial challenge test (BCT), 311–312
- Bronchodilator drugs
- applications of, 82*t*, 90–91
 - interpreting drug concentration of, 82*t*
- Bronchodilator responsiveness test, 307
- Broth, bacteria growth medium and types of, 407*t*
- Broth macrodilution susceptibility testing, 413*f*, 414
- Broth microdilution susceptibility testing, 414–415, 414*f*, 420
- BSA. *See* Body surface area
- BTP. *See* β -trace protein
- B-type natriuretic peptide (BNP), diagnostic test for, 8
- Buffers, acid-base imbalance and role of, 290
- BUN. *See* Blood urea nitrogen
- C**
- C3, definition and normal range of complement protein, 498
- C4, definition and normal range of complement protein, 498
- C-peptide, to differentiate between Type 1 and Type 2 DM, 167
- C-reactive protein
- correlation with serum albumin, 278*f*
 - definition and normal range of, 499
 - not clinical marker for nutritional status, 280–281
- C-serotonin release assay, 383
- C-urea breath test, drugs that affect, 13
- CA 15-3, definition and normal range of cancer antigen and tumor marker, 515*t*, 517
- CA 19-9, definition and normal range of cancer antigen and tumor marker, 515*t*, 519–520
- CA 27.29, definition and normal range of cancer antigen and tumor marker, 515*t*, 517
- CA-125, definition and normal range of cancer antigen and tumor marker, 515*t*, 517–519
- CAC. *See* Coronary artery calcium
- Caffeine
- therapeutic range and clinical consideration, 91
 - treatment of neonatal apnea, 90
- CAH. *See* Congenital adrenal hyperplasia
- Calcium
- body regulation of, 582
 - description, physiology, normal range, 245–248, 246*f*
 - effect of vitamin D, calcitonin, parathyroid hormone on, 248
 - EKG and intracellular potential for, 247*f*
 - measurement of pediatric and adult, 583
 - pediatric and adult normal ranges, 582
 - See also* Serum calcium
- Calcium channel blockers, effect on calcium of, 247
- Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER), 576
- Candida, MIC breakpoint for genus and species of, 462*t*
- CaO₂. *See* Arterial oxygen content
- CAP. *See* College of Pathologists; Community-acquired pneumonia
- Capillary electrophoresis (CE), components, uses, advantages of, 26–28
- Capillary gel electrophoresis (CGE), uses of, 28–29
- Capillary lateral flow design, CLIA-waived POC tests for HIV, 62
- Capillary puncture, blood sampling method/sites for pediatric patients, 574–575
- Capillary zone electrophoresis (CZE), components and use of, 27–28
- Carbapenemase enzymes, chromosomal or plasmid-mediated, 418–419
- Carbon monoxide (CO) breath test, 312–313
- Carbonic acid (H₂CO₃), 290
- Carbonic acid-bicarbonate buffering system, 290
- Carcinoembryonic antigen (CEA)
- definition, normal range, tumor marker, 515*t*, 517
 - elevated level of, 518*b*
- Carcinoma, nonmuscle-invasive (NMIBC), 5*b*
- Cardiac drugs, interpreting drug concentrations of, 84*t*, 101–104
- Cardiac enzymes, types of, 142
- Cardiac output (CO), equation for, 140
- Cardiac physiology, 139–140
- Cardiac-specific troponin (cTn)
- I and T diagnostic test of serum, 8
 - subunit biomarker for myocardial infarction, 140–141
- Cardiovascular disease, incidence in U.S. of, 149
- Cardiovascular pharmacogenetics, 126*b*
- Casts, types of urinary, 213–214, 213*t*
- CBC. *See* Complete blood count
- CBC with differential, meaning of, 357
- CC. *See* Capillary electrophoresis

- CD4⁺ T lymphocyte count, test for HIV, 480
- CDC. *See* Centers for Disease Control and Prevention
- CDTM. *See* Collaborative drug therapy management
- CE. *See* Capillary electrophoresis
- CEA. *See* Carcinoembryonic antigen
- Cefoxitin disk diffusion test, 419
- Centers for Disease Control and Prevention (CDC)
- algorithm to interpret CLIA-waived POC tests for influenza A and B, 63
 - annual number of cases of HCV, 60
 - pharmacist training for CLIA-waived POC tests, 68
 - pharmacy training for HIV testing, 62
 - recommend testing sequence for HCV, 60
 - standardized testosterone assays, 629
 - technical info on CLIA and POC from, 51
 - website for CLIA-waived POC tests, 52*t*
- Centers for Medicare and Medicaid Services (CMS)
- oversee CLIA, 51
 - regulate facilities doing lab tests/POCT, 52
 - website for CLIA-waived tests, 52*t*
- Central venous oxygen saturation (ScvO₂), taken from central venous catheter, 289–290
- Cerebrospinal fluid, antigen testing for fungi in, 457
- Ceruloplasmin, indicator of copper status, 255
- CESI* gene, 389
- CGE. *See* Capillary gel electrophoresis
- CGM. *See* Continuous glucose monitoring
- Chain of custody, SAMHSA guidelines for drug specimen, 547
- Checkerboard technique, description of, 418
- Chemical analysis, semiquantitative tests and urine dipsticks, 214–220
- Chemical ionization (CI), principles, components, uses of, 34
- Chemiluminescence, description and components of, 22
- Chemiluminescent detection method, 629
- Chemistry analyzers, laboratory, 20
- Child, definition of age group, 574*t*
- Chlamydia, laboratory tests to diagnose, 436
- Chlamydia trachomatis*, cause of chlamydia, 436
- Chloride, definition and physiology of, 242
- Chloridometer, 25
- Cholestasis
- symptoms and diagnosis of, 333*b*
 - types of, 319
- Cholestatic liver disease, description of, 316–317, 318–320, 319*t*
- Cholesterol
- AHA guidelines for, 149
 - combined enzymatic method
 - CLIA-waived POC test for, 59
 - elevated level as cause of ASCVD, 58
 - identifying candidates for CLIA-waived POC test for, 58
 - variants that affect CLIA-waived POC test for, 59
- See also* Total cholesterol
- Cholesterol Reference Method Laboratory Network, NRS/CHOL standards and, 58
- Chromatography, components, types, and use of, 29–30
- Chromium, physiology, normal range, deficiency/excess of, 259–260
- Chromogen, serum creatinine level not accurate due to noncreatinine, 203
- Chromophores, 59
- Chronic disease, CLIA-waived POC testing and medication adjustment for, 53
- Chronic kidney disease (CKD)
- anemia associated with, 367–368
 - definition and classification of, 202
 - KDIGO guidelines for, 591
 - stages of, 207*t*
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, 202, 205*b*, 207–208
- Chronic myelogenous leukemia (CML)
- cytogenetic and molecular response of, 522*t*
 - Philadelphia chromosome in, 521
- Chronic obstructive pulmonary disease (COPD)
- postbronchodilator airflow limitation, 305
 - spirometry to diagnose, 305*b*
- Chronic pain, guidelines/testing to prevent abuse from drugs for, 558, 559*t*
- Chronic Prostatitis Symptom Index, from NIH, 648
- Chronic renal failure, calcium and phosphate disorders in, 253–254*b*
- Chronotropic effect, management of arrhythmia with digoxin, 102
- Chvostek sign, hypocalcemia and, 250
- Chylomicron, description of, 150, 150*f*, 151*t*
- CI. *See* Chemical ionization
- Circadian rhythm, description and lab test results affected by, 12
- CK. *See* Creatine kinase
- CK-MB. *See* Creatine kinase-myocardial band
- CKD. *See* Chronic kidney disease
- CKD-EPI. *See* Chronic Kidney Disease Epidemiology Collaboration
- Clarification of Optimal Anticoagulation Through Genetics (COAG), 129–130
- CLIA Certificate of Waiver, issued by CMS, 52
- CLIA-88. *See also* Clinical Laboratory Improvement Amendments
- CLIA-waived POC tests and testing
- CDC website for professional education/information for, 52*t*
 - CMS website list by CPT of, 52*t*
 - government websites with information on, 52*t*
 - legal and regulatory barriers to pharmacists doing, 69
 - lipid types, 158
 - outpatient pharmacies use of, 51
 - performance characteristics/applications, 53–54
 - pharmacy degree programs do not include infectious disease, 69–70
 - qualitative and quantitative, 53
 - shortage of primary care providers so pharmacists will do more, 70
 - steps to take before offering, 68–69
 - uses and applications of, 56–67
- See also* Clinical Laboratory Improvement Amendments; Point-of-care testing
- Clinical and Laboratory Standards Institute (CLSI)
- criteria for MIC results, 412
 - standards for cholesterol tests, 59
 - standards set by, 20
- Clinical drug trials, FDA looks at drug concentration versus response relationship in, 79
- Clinical Laboratory Improvement Amendments of 1988, 14, 51
- Clinical Pharmacogenetics Implementation Consortium (CPIC)
- clinical practice guidelines for genotype, 132
 - guidelines from, 120
 - standardized terms for allele function and phenotype, 123
- Clostridium difficile*, diagnosis, tests, and treatment for, 344
- Clot degradation test, definition and use of, 392
- CLSI (Clinical and Laboratory Standards Institute)
- Performance Standards and Guidelines for Antimicrobial Susceptibility Testing, 428
- CML. *See* Chronic myelogenous leukemia
- CMP. *See* Comprehensive metabolic panel
- CMS. *See* Centers for Medicare and Medicaid Services
- CO. *See* Cardiac output
- Coagulation, factors that inhibit or promote, 377–378
- Coagulation cascade, function of, 378, 378*f*
- Coagulation studies, factors that interfere with, 387
- Coagulation tests, lack of standardization of most common types of, 385–386

- Cocaine, interpretation of workplace testing for, 552*b*
- Cockcroft Gault equation, 14*b*
- Cockcroft-Gault equation, estimation of creatinine clearance, 206
- Cockcroft-Gault equation, glomerular filtration rate equation versus, 208
- Codeine, *CYP2D6* gene and, 124, 125*b*
- Colitis, description, causes, diagnosis of, 343–344
- Collaborative drug therapy management (CDTM), CLIA-waived POC testing with, 56
- Collaborative practice agreement (CPA), CLIA-waived POC testing with, 56
- College of Pathologists (CAP), 132
- Colligative properties, 23
- Colloid osmotic pressure (COP), definition of, 23
- Colloid osmotic pressure (COP) osmometer, components of, 23–24
- Colonization, in a biologic specimen, 408
- Colony-stimulating factors, 357
- Colorimetry, description of, 170–171
- Combined enzymatic method, CLIA-waived POC test for cholesterol, 59
- Community-acquired pneumonia (CAP), 411
- Community/corporate health screenings, for ASCVD by pharmacist at, 58
- Community screenings, pharmacists and CLIA-waived POC tests for diabetes of, 56
- Complement
 - definition and pathways to activate the system of, 497–498
 - JIA and presence of, 504
 - SLE and presence of, 505
 - test for rheumatoid arthritis, 503
- Complete blood count (CBC)
 - normal range dependent on age, 11
 - tests included in, 356*t*, 357–359
- Complexity, FDA classifies POC tests by, 51
- Comprehensive metabolic panel (CMP), lab tests included in, 8
- Conductometric method, CLIA-waived POC test for hemoglobin using, 58
- Conductometry, definition and uses of, 26
- Congenital adrenal hyperplasia (CAH), definition and cause of, 611–612
- Conjugated bilirubin, pediatric and adult normal ranges, 593
- Contamination, definition and occurrence of, 409
- Continuous glucose monitoring (CGM)
 - FDA accuracy requirement for, 172
 - Smartphone app for, 171
 - subcutaneous sensor for, 171
- Continuous pulse oximetry, 312
- Coomassie dye, 27
- COP. *See* Colloid osmotic pressure
- COPD. *See* Chronic obstructive pulmonary disease
- Copper, description, physiology, normal range of, 254
- Coronary artery calcium (CAC), recommended by ACC/AHA, 157–158
- Corporate health/wellness programs, CLIA-waived POC tests for diabetes for, 56
- Corticotropin. *See* Adrenocorticotropic hormone
- Corticotropin-releasing hormone (CRH), pregnancy affects, 13
- Cost efficiency, automation as driver in clinical laboratory, 20
- Cosyntropin, timing of lab test for, 11
- Cosyntropin stimulation test, for adrenal insufficiency, 188
- Cosyntropin test, example of diagnostic test, 8
- Coulometry, principles, components, uses of, 24–25
- Coulter principle, basis of cell counting/sizing, 35
- COVID-19
 - identifying candidates for POC tests for, 67
 - novel SARS-CoV-2 virus causes, 66
 - performance characteristics of, 67
 - use of antigen detection and molecular tests for, 67
- COVID-19 POC tests, not CLIA-waived, 67
- CPA. *See* Collaborative practice agreement
- CPA/CDTM agreement
 - pharmacist adjusts drug doses, schedules testing/physician follow-up under, 56
 - pharmacist authorization from patient's primary care provider, 69
 - pharmacist can screen/manage ASCVD, 58
 - pharmacist monitors renal/liver function with blood chemistries, 59
 - pharmacist prescribes antibiotic for urinary tract infection, 59
- CPE. *See* Cytopathologic effect
- CrCl. *See* Creatinine clearance
- Creatine kinase (CK)
 - isoforms of, 4
 - location, and function of isoenzymes of, 142
 - timing of postmyocardial infarction level of, 9, 11
- Creatine kinase-myocardial band (CK-MB), estimate size of infarction with, 141
- Creatinine
 - description and normal range for serum, 203
 - drugs that affect, 13
 - normal range dependent on age, 11
 - See also* Serum creatinine
- Creatinine clearance (CrCl)
 - determined from urinary creatinine, 589
 - estimated from glomerular filtration rate, 589
 - kidney function and, 202
 - measurement/equations for, 205–206
 - standardization of basis for, 589
- CREST (mnemonic for several diseases), 495
- CRH. *See* Corticotropin-releasing hormone
- Criminal justice system, purpose of drug screening in, 548
- Critical value, definition of, 6
- Crohn disease
 - copper deficiency and, 255
 - malnutrition risk for, 282*b*
- Crystals
 - morphology of synovial fluid, 500*t*
 - types of urinary, 214, 215*f*
- cTn. *See* Cardiac-specific troponin
- Culture, identifying fungi by, 455
- Culture media, types of nutritive, differential, and selective, 406
- Cuproproteins, copper and, 255
- Cushing syndrome, causes and symptoms of, 186–187
- Cutoff value, sensitivity of quantitative test and threshold or predefined, 53
- Cuvette, analytical or sample, 21, 21*f*, 22
- Cyclic voltammetry, 26
- Cyclooxygenase, platelet, 378
- CYP2C9* gene, 124–125, 127*f*, 388
- CYP2C19* gene
 - clopidogrel metabolism and effect of, 385
 - no-function alleles in, 124
- CYP2D6* gene, codeine pharmacogenetics and, 124, 125*b*
- CYP3A4* gene, 389. *See also* Cytochrome P450 3A4 enzyme
- CYP3A5* gene, 125
- CYP4F2* gene, definition of, 388
- CYP450*. *See* Cytochrome P450
- Cystatin C
 - description and normal range for, 202–203
 - equation for, 207–208
 - kidney function and, 202
- Cystoscopy, recurrence surveillance of bladder urothelial carcinoma by, 5*b*
- Cytochrome P450 3A4 enzyme, in grapefruit juice, 13
- Cytochrome P450 family, isoenzymes, 12
- Cytochrome P450 system, description of, 123
- Cytometry, definition and types of, 35–37
- Cytomics, definition of, 35
- Cytopathologic effect (CPE), viruses produce, on cells, 472

- Cytoplasmic antineutrophil cytoplasmic antibody (cANCA), test for, 496
- Cytotoxic drugs, 84*t*, 104–105
- Cytotoxicity assay, for pseudomembranous colitis, 344
- CZE. *See* Capillary zone electrophoresis
- D**
- D-Dimer, definition, uses, and normal range of, 393, 394, 394*f*
- DailyMed (National Institutes of Health), description of, 47, 49*b*
- DAT. *See* Direct agglutination test
- DCCT. *See* Diabetes Control and Complications Trial
- DEA. *See* Desethylamiodarone
- Dehydration, interpretation of lab tests in, 14*b*
- Dehydroepiandrosterone (DHEA), 626
- Delayed-release drug, lowest concentration versus peak concentration for, 86*f*
- Densitometry, description, components, and uses of, 27, 29
- Deoxyribonucleic acid (DNA), screening test for, 8
- Desethylamiodarone (DEA), metabolite of amiodarone, 103
- Designer drugs, not detected on routine drug screening, 548, 549*t*, 560*b*
- Detoxification, laboratory tests associated with, 325
- DFA. *See* Direct fluorescent antibody test
- DHEA. *See* Dehydroepiandrosterone
- DHT. *See* Dihydrotestosterone
- Diabetes
- as cause of secondary dyslipidemia, 151
 - CLIA-waived POC test for detection/management of, 56
 - CLIA-waived POC urinalysis to monitor, 59
 - identifying candidates for CLIA-waived POC test for, 56
 - number of Americans with undiagnosed, prediabetes, or, 56
 - See also* Diabetes mellitus; Diabetes insipidus; Gestational diabetes
- Diabetes Control and Complications Trial (DCCT), HgbA1c correlated with complications, 56
- Diabetes insipidus (DI)
- drugs that cause, 232, 233*t*
 - physiology, causes, types of, 188–189
- Diabetes mellitus (DM)
- cardiovascular disease leading cause of death in, 176
 - laboratory tests to diagnose, 167, 168*t*, 169–170
 - type 1 characteristics of, 166, 166*t*
 - type 2 characteristics of, 166–167, 166*t*
 - type 2 HgbA1c and, 57*b*
 - types of, 166–167
- Diabetic ketoacidosis (DKA), causes and symptoms of, 172–174, 173–174*b*
- Diagnostic tests, definition, features, purpose, examples of, 8, 8*t*
- Diastolic heart failure, definition of, 142
- DIC. *See* Disseminated intravascular coagulation
- Diet, serum glucose and lipid profiles affected by, 13
- Diffusion capacity tests, definition and types of lung, 310–311
- Digital rectal examination, of prostate gland, 638
- Digoxin
- importance of sample timing with, 87, 87*b*
 - inappropriate timing of blood sample, 102
 - serum concentrations versus myocardial tissue concentrations, 102*f*
 - therapeutic range and clinical considerations, 101–103
 - timing of laboratory test and serum concentrations of, 9
 - toxicities from, 102*t*
- Digoxin assay, 6
- Digoxin immune fragment antibody, digoxin toxicity treated with, 555, 555*f*
- Dihydropyrimidine dehydrogenase (DPD), deficiency of, 128
- Dihydrotestosterone (DHT), physiologic effect of, 626*t*
- Dilute thrombin time (dTT), definition of, 392
- Diplotype, definition of, 120*t*
- Direct agglutination test (DAT), description and uses of, 32, 366
- Direct agglutination, description and uses of, 32
- Direct antigen detection, of a virus, 473
- Direct bilirubin
- definition of, 4
 - normal range of conjugated/soluble, 321–322, 322*f*
- Direct Coombs test, 13, 366
- Direct fluorescent antibody test (DFA), 436
- Direct oral anticoagulant (DOAC), 380, 387*t*
- Direct thrombin inhibitor (DTI), 380, 381*t*
- Disease genetic testing, versus pharmacogenetic testing, 120
- Disk diffusion susceptibility testing, Kirby-Bauer method of, 415–416, 415*f*
- Disseminated intravascular coagulation (DIC)
- formation of D-dimers in, 394*f*
 - laboratory differential diagnosis of, 391*b*, 395*t*
- Diuretic drugs, lab tests affected by, 13
- Diurnal variability, effect on lab test results of, 12
- DKA. *See* Diabetic ketoacidosis
- DLCO, definition of, 311
- DM. *See* Diabetes mellitus
- DNA. *See* Deoxyribonucleic acid
- DO₂. *See* Oxygen delivery
- DOAC. *See* Direct oral anticoagulant
- Dome nomogram, categories for salicylate poisoning on, 554
- Doping, definition of, 558
- Dosage adjustments, for linear and nonlinear drug behavior, 88
- Dose rate, influenced by dosing interval and amount of dose, 88
- Dosing interval
- factors that affect, 86
 - factors that determine fluctuation within, 86
- Double-stranded DNA antibodies, definition and normal values of, 494–495
- Driving under the influence, number of Americans reporting, 543
- Drug, interpretation of result of non-steady-state concentration of, 11
- Drug-laboratory test interaction
- medical literature can confirm, 46–47
 - categories/examples of, 12–13
- Drug abuse, high school seniors and type of drug used in, 546*t*
- Drug administration, importance of documenting time of, 80*b*
- Drug concentration
- appropriate interpretation of, 77, 79*t*
 - information to request/evaluate, 77
 - measure at steady state, 81, 82–85*t*, 85
 - prompt-release versus sustained-release formation and, 86*f*
 - reasons when and why results do not make sense, 79*t*
 - sample not drawn at desired time and how to interpret, 88
- Drug concentration monitoring, goals/indications for, 76
- Drug databases, website to access, 49*b*
- Drug disposition reactions, phases of, 123
- Drug interference
- identifying, 44–45
 - reasons for and when to suspect, 45, 46*b*
 - steps to take in managing, 46
- Drug metabolism, enzyme polymorphism and, 11–12
- Drug monitoring
- future of therapeutic, 108–109
 - overuse or underuse debate about, 75
- Drug screening, purpose in criminal justice system, 548
- Drug test, role of medical review officer in reviewing results of, 547–548
- Drug therapy, rheumatic diseases and tests to monitor, 506–507, 507–508*t*
- Drugs.com, online drug database, 47

- DTI. *See* Direct thrombin inhibitor
- dTT. *See* Dilute thrombin time
- Dual-energy absorptiometry, to evaluate malnutrition, 281
- DuBois formula, equation for body surface area, 589
- DynaMed Plus, online drug database, 47, 49*b*
- Dyslipidemia
definition, classification of primary and secondary, 151, 152*t*, 153*t*
risk factor for ASCVD, 149
- Dysrhythmia, definition of, 139
- D-Zone test, for clindamycin resistance, 420
- E**
- Ecarin clotting time (ECT), definition and use of, 392
- ECT. *See* Ecarin clotting time
- ECW. *See* Extracellular water
- Effective strong ion difference (eSID), 290
- eGFR. *See* Estimated glomerular filtration rate
- EGFR. *See* Epidermal growth factor receptor
- EI. *See* Electron ionization
- EIA. *See* Enzyme immunoassay
- Electrochemistry, definition and types of, 24
- Electrodes, types of, 24
- Electrolytes
CLIA-waived POC test for, 59
intracellular water versus extracellular water composition of, 577
recommended dietary intake of, 230*t*
traditional units converted to SI units, 230*t*
types of, 229–235
urine, 218–219
- Electromotive force, 26
- Electron ionization (EI), principles, components, uses of, 34
- Electron microscopy (EM), detection of viruses by, 473
- Electronic medical record (EMR), combining biorepositories with, 123
- Electronic Medical Records and Genomics (eMERGE) description of, 123
- Electroosmotic flow (EOF), 28
- Electrophoresis, principles, components, types, uses of, 26–29
- Electrospray ionization (ESI), principles, components, uses of, 34
- ELISA. *See* Enzyme-linked immunosorbent assay
- eMERGE. *See* Electronic Medical Records and Genomics
- Emergency Use Authorization (EUA)
definition for COVID-19 of, 67
from FDA for POC tests, 51–52
- EMIT. *See* Enzyme-multiplied immunoassay
- EMR. *See* Electronic medical record
- Enantiomers
activity and pharmacokinetic behavior of, 77
pharmacokinetics affected by racemic mixture of, 81
- Enantiomeric drug pairs, racemic mixture of, 90
- Endpoint, definition of, 24
- Enzyme Immunoassay (EIA)
components and advantages of, 32–33
detection of fungi by, 458
molecular absorption spectrophotometer and, 23
- Enzyme polymorphism, drug metabolism and examples, 11–12
- Enzyme-linked immunosorbent assay (ELISA)
anti-HCV, 330
C. difficile infection, 344
heparin-induced thrombocytopenia, 383
principles, components, uses of, 25*t*, 33
quantitative assay for ACPA by, 493
viral infectious diseases, 56
- Enzyme-multiplied immunoassay (EMIT), description and use of, 25*t*, 33, 33*f*
- EOF. *See* Electroosmotic flow
- Eosinophils, definition, function, and normal range of, 369
- Epidermal growth factor receptor (EGFR), 130, 516*t*
- Epigenetics
definition and use of, 38–39
personalized medicine and, 19
- Epitope, definition of, 31
- Epsilometer test (Etest), description of, 416, 416*f*
- Equation
CKD-EPI Collaboration creatinine, 207–208
CKD-EPI Collaboration cystatin C, 207–208
Cockcroft Gault, 14*b*
creatinine clearance, 589
Dubois-Dubois body surface area, 206, 589
glomerular filtrate rate (GFR), 208
Haidukewych, 94
nitrogen balance, 280
Modification of Diet in Renal Disease (MDRD) for glomerular filtration rate, 204, 206*b*, 207
Mostellar body surface area, 206, 589
Nernst, 24
predictive linear regression, 90
Schwartz bedside glomerular filtration rate, 590
Sheiner, 89
Tozer, 89–90
Winter-Tozer, 94
- Erectile dysfunction
comparison of organic and psychogenic, 632*t*
definition, symptoms, and causes, 631–633, 631–632*t*
diagnostic tests for, 633*t*
low serum testosterone and, 630*b*
- Erection Hardness Scale, 634, 634*t*
- Error limits, manufacturer's package insert for CLIA-waived POC test has, 53
- ERS. *See* European Respiratory Society (ERS), 307
- ERV. *See* Expiratory reserve volume
- Erythrocyte sedimentation rate (ESR), definition and normal range of, 357, 359, 498–499
- Erythrocytes (RBCs), pediatric and adult normal ranges, 594
- Erythropoietin, source of, 357
- ESBL. *See* Extended-spectrum- β -lactamase
- ESI. *See* Electrospray ionization
- eSID. *See* Effective strong ion difference
- ESR. *See* Erythrocyte sedimentation rate
- Estimated glomerular filtration rate (eGFR), kidney function and, 202
- Estradiol, pediatric, adult, and female normal ranges, 603–604, 610*t*
- Estrogen receptor (ER)
personalized cancer treatment with tumor marker, 516*t*
response to treatment predicted by, 513
use of assay, 520
- Estrogen status, progesterone challenge test, 610
- Ethanol, methanol and ethylene glycol poisonings treated with, 554
- Ethnicity, laboratory test results affected by, 11
- EUA. *See* Emergency Use Authorization
- Euglycemic diabetic ketoacidosis, 172
- European Association of Andrology, 629
- European Association of Urology, 629
- European Committee on Antimicrobial Susceptibility Testing (EUCAST), 461
- European League Against Rheumatism (EULAR), 501
- Euthyroid state, definition of, 178
- Exercise challenge test, purpose of, 312
- Expiratory reserve volume (ERV), definition of, 310, 310*f*
- Extended-spectrum- β -lactamase (ESBL), 418
- Extracellular water (ECW), pediatric versus adult, 576–577, 577*f*
- Extrahepatic cholestasis, definition, causes, and laboratory tests for, 320

- F**
- Facts and Comparisons, online drug database, 47, 49*b*
- False negative (FN), 3, 4*t*
- False positive (FP), 3, 4*t*
- FANA. *See* Fluorescent antinuclear antibody
- Faraday constant, 24
- Faraday law, 24–25
- Fast atom bombardment, ionization technique of, 34
- Fasting, glucose and lipid levels after, 13
- Fasting blood glucose (FBG)
normal range dependent on age, 11
screening test for, 8
- Fasting plasma glucose (FPG), to assess glucose control, 168
- Fatty liver, causes of, 323
- FBG. *See* Fasting blood glucose
- FDA. *See* Food and Drug Administration
- FDP. *See* Fibrin degradation product
- Fecal antigen test, for *H. pylori*, 342
- Fecal occult blood (FOB), screening test for, 8
- Fecal transplantation, for *C. difficile* infection, 344
- Federal Bureau of Investigation Laboratory, 556
- FDA (U.S. Food and Drug Administration)
accuracy requirement for glucose tests/monitors, 172
analytes in POC tests and EUAs from, 52*t*
classifies POC tests by complexity and public health risk, 51
determines drug concentration response early in clinical trials, 79
Emergency Use Authorization for POCT, 51–52
regulates POC test manufacturers, 51
Table of Pharmacogenetic Associations from, 120
Table of Pharmacogenomic Biomarkers in Drug Labeling from, 120
- FeNO, FENO. *See* Fractional exhaled nitric oxide
- Ferritin, definition of, 364
- FEV₁. *See* Forced vital capacity in 1 second
- FEV₁/FVC, definition of ratio of, 303, 304
- Fibrin degradation product (FDPs)
clot degradation and, 380
definition and normal range of, 393
thrombolytic therapy and elevated, 393
- Fibrinogen assay, definition, use, and normal range of, 391–392
- Fibrinolysis, definition, 380
- Fibromyalgia, definition, symptoms, and laboratory tests for, 506
- Film Array multiplex PCR system, for rapid identification of bacteria by, 408
- FiO₂. *See* Fraction of inspired oxygen
- First Databank, online drug database, 47
- FISH. *See* Fluorescent in situ hybridization
- Flame emission photometer, also known as atomic emission spectrophotometer, 21
- Flow cytometry, principles, components, use of, 35, 36, 37*f*
- Flow-volume curve or loop
obstructive and restrictive pulmonary disease and, 306*f*
spirometry and, 302, 304*f*, 305
- Fluid status, tests for assessing, 235–244
- Fluorescence, description and components of, 22
- Fluorescence-activated sorting, 370
assay of blood or bone marrow, 520
components and uses of, 37
- Fluorescence polarization immunoassay (FPIA), components and use of, 25*t*, 33–34
- Fluorescent antinuclear antibody (FANA) test, indirect, 496
- Fluorescent in situ hybridization (FISH)
- Fluorescent polarization, 22
- Fluorescent treponemal antibody absorption (FTA-ABS) test, 437
- Fluorometry
also known as molecular emission spectrophotometry, 22
principle of, 36
- Fluorophore, definition of, 22
- FN. *See* False negative
- FOB. *See* Fecal occult blood
- Folate concentration, definition and normal range of, 363
- Folic acid, sources, absorption, and tests for, 363
- Folic acid deficiency, causes of, 363
- Follicle-stimulating hormone (FSH)
drugs affecting lab value of, 603*t*
pediatric and adult normal range, 602–603
pediatric and female normal range, 610*t*
- Follicular phase, hormone levels during, 601
- Fomepizole, ethylene glycol poisoning treated with, 554
- Food and Drug Administration (FDA)
biomarker definition by, 4
home-testing kits approved by, 15
- Forced vital capacity (FVC), definition of, 303
- Forced vital capacity in 1 second (FEV₁), definition of, 303, 304
- Forensic issues, urine drug screens and serum drug concentrations, 556
- Forward-scattered light (FSC), 36
- FP. *See* False positive
- FPG. *See* Fasting plasma glucose
- FPIA. *See* Fluorescence polarization immunoassay
- Fraction antigen-binding (Fab) site, on immunoglobulins, 491
- Fraction of inspired oxygen (FiO₂), 288
- Fractional excretion of sodium (FE_{Na}), description and normal range, 235–236
- Fractional exhaled nitric oxide (FeNO, FENO), 5, 8, 313
- Framingham Study, HDL level protective against cardiovascular risk, 156
- FRC. *See* Functional residual capacity
- Free T₄
availability and performance of assay of, 181*t*
laboratory test for thyroid disease, 179
thyroid and nonthyroid disease levels of, 180*t*
- Free T₄ index, laboratory test for thyroid disease, 183
- Free testosterone, pediatric and adult normal ranges, 629
- Freezing-point depression osmometer, 23
- Fructosamine, laboratory test for diabetes, 170
- FSC. *See* Forward-scattered light
- FTA-ABS. *See* Fluorescent treponemal antibody absorption
- Full-term neonate, definition of age group, 574*t*
- Functional residual capacity (FRC), definition of lung, 309–310, 310*f*
- Fungi, antigen testing and detection of, 457
- Fungi
description and categories of, 445–447
genus and species names of medically important, 446*t*
laboratory tests for identification of, 447, 448–453*t*
molecular diagnostic tests to identify, 459–460
stains to enhance microscopic detection of, 454–455*t*
- Fungitell assay, 459
- FVC. *See* Forced vital capacity
- G**
- G6PD. *See* Glucose-6-phosphate dehydrogenase
- G6PD deficiency, definition and causes of hemolysis from, 367
- GAD. *See* Glutamic acid decarboxylase
- GADA. *See* Glutamic acid decarboxylase autoantibodies
- Gallstone disease, abdominal pain and, 341*b*
- Gamma-glutamyl transferase (GGT), definition and normal range of, 321
- Gamma-glutamyl transpeptidase (GGTP), definition and normal range of, 321
- Gas chromatography (GC), principles and use of, 29–30, 25*t*, 30*f*

- Gas chromatography with mass spectrometry (GC-MS), to confirm result of urine drug screen, 545
- GAS. *See* Group A streptococcus
- Gastric cancer, *Helicobacter pylori*-associated, 342
- Gaussian (random) value distribution, reference population to have, 5–6, 6f
- GC. *See* Gas chromatography
- GDM. *See* Gestational diabetes mellitus
- Gel electrophoresis, components of, 26–27
- Gender, laboratory test results affected by, 11
- Gene, definition of, 120t
- “Gene chips,” 40
- Genetic disease, PCR used to identify, 38
- Genetic polymorphism, examples of, 12
- Genetic testing, future trends in, 16
- Genetics, laboratory test results affected by, 11
- Geneva score, probability of venous thromboembolism, 393
- Genomics
- definition and use of, 38–39
 - key terms for, 120t
 - personalized medicine and, 19
- Genotype
- definition of, 120t
 - response to certain drugs determined by, 81
- Genotyping, definition of preemptive, 119
- Genotyping platforms, tests for pharmacogenetic-related genes, 131–132
- Geriatric reference range, laboratory test results and, 11, 12t
- Germline mutations, definition of heritable, 129
- Germline variant, definition of, 120t
- Germline variation
- CPIC guidelines for drugs with, 121–122t, 132
 - genotype-guided therapy and, 129
- Gestational age (GA), definition of, 574t
- Gestational diabetes mellitus (GDM), pregnancy and 166, 167
- GFR. *See* Glomerular filtration rate
- Gleason score, of prostate gland tumor, 639, 647–648
- Global Initiative for Asthma, 2020 guidelines, 90
- Global Initiative for Chronic Obstructive Lung Disease (GOLD), 90, 302–303, 304
- Global Lung Function Initiative (GLI), spirometry reference values from, 302
- Glomerular filtration rate (GFR)
- age-related development of, 588–589
 - equations for estimating, 205b
 - piperacillin-tazobactam dose based on, 590–591b
 - serum cystatin C used to estimate, 591–592
- Glucagon, functions of, 165
- Gluconeogenesis, definition of, 165
- Glucose, description and normal range for urine, 218
- Glucose-6-phosphate dehydrogenase (G6PD), erythrocytes and, 128
- Glucose-6-phosphate dehydrogenase deficiency (G6PD), gender/ethnicity and, 11
- Glucose homeostasis, process of, 165–166
- Glucose meters, website for list and features of, 171
- Glucose monitors, for children and visually impaired, 171
- Glucose test
- environmental factors affecting, 171–172
 - FDA accuracy requirement for, 172
- Glucose tolerance factor (GTF), definition of, 259
- Glutamic acid decarboxylase (GAD), 167
- Glutamic acid decarboxylase autoantibodies (GADA) test, 167
- Glycated hemoglobin. *See* Glycosylated hemoglobin
- Glycogen, glucose stored in the liver, 165
- Glycogenesis, definition of, 165
- Glycogenolysis, definition of, 165
- Glycosuria, diabetes mellitus and, 219b
- Glycosylated hemoglobin (A1c, HbA1c)
- biomarker for blood sugar level, 4
 - CLIA-waived POC test for, 56
 - diabetic patient compliance and, 168–170
- GOLD MARK, mnemonic for causes of anion gap acidosis, 292
- Gonadotropin-releasing hormone (GnRH), 625
- Gonorrhea, laboratory tests to diagnose, 435–436
- Gout, hyperuricemia and, 510b
- GPA. *See* Granulomatosis with polyangiitis
- Gram stain
- bacteria identified with, 405–406t
 - identification of fungi by, 454, 454t
 - microorganisms that cannot be identified with, 404
 - steps in procedure of, 404
- Granulocytes, definition of, 368–369
- Granulomatosis with polyangiitis (GPA), quantitative and qualitative assays for, 496–497
- Grapefruit juice, bioavailability of drugs altered by, 13
- Gridley stain, for identification of fungus, 454, 454t
- Group A streptococci (GAS)
- CLIA-waived POC tests for, 55
 - diagnosing viral sore throat versus, 64
 - identifying candidates for CLIA-waived POC test, 64
 - performance characteristics of CLIA-waived POC test, 64, 66
 - types of antigen detection methods in CLIA-waived POC tests, 66
- Growth media, used to identify fungi, 456–457t
- GTF. *See* Glucose tolerance factor
- ## H
- H₂CO₃. *See* Carbonic acid
- Haidukewych equation, total phenytoin concentration, 94
- Hair, drug toxicity strengths and weaknesses of specimen, 557t
- Half-life
- constant infusion versus intermittent infusion and, 85f
 - prolonged at higher concentrations for phenytoin, 88
- HAP. *See* Hospital-acquired pneumonia
- Haplotype, definition of, 120t
- Hapten type 1, hemolysis from, 367
- Hartford method, aminoglycoside dosing and, 97
- HAV. *See* Hepatitis A virus
- HbA1c. *See* Glycosylated hemoglobin
- HbCag. *See* Hepatitis B core antigen
- HBeAg. *See* Hepatitis B extracellular antigen
- HBsAg. *See* Hepatitis B surface antigen
- HBV. *See* Hepatitis B virus
- HCG. *See* Human chorionic gonadotropin
- hCG, HCG. *See* Human chorionic gonadotropin
- HCO₃⁻. *See* Bicarbonate
- Hct/HCT. *See* Hematocrit
- HCV. *See* Hepatitis C virus
- HDLs. *See* High-density lipoproteins
- HDV. *See* Hepatitis D virus
- Health Insurance Portability and Accountability Act, federal privacy law, 68
- Healthy People 2020, goal for total cholesterol (TC), 149
- Heart disease, leading cause of death in U.S., 58
- Heart failure
- definition and etiology of, 142–143, 143b
 - kidney function in, 211b
 - laboratory tests for, 143–145
- Helicobacter pylori*, tests for, 342
- Hematocrit (Hct, HCT)
- definition and normal range of, 356t, 358
 - pediatric and adult normal ranges, 594–595
- Hematologic tests, age-related differences in, 594–596
- Hematology analyzer, principles of, 20, 35–36

- Hematopoiesis
 definition and sites of, 355–356, 355f
 inhibitors of, 357
- Hemochromatosis, definition, types, symptoms, tests for, 331–332
- Hemoconcentration, lab tests affected by, 13
- Hemodilution, laboratory test results affected by, 13, 14t
- Hemoglobin (Hgb)
 definition and normal range of, 356t, 358
 description and normal range for urine, 217
 pediatric and adult normal ranges, 594
 performance characteristics of CLIA-waived POC test, 58
 physiologic factors affecting measurement of, 58
 structure of normal adult, 27
- Hemoglobin (Hgb) and hematocrit (Hct), CLIA-waived POC tests for, 57
- Hemoglobin electrophoresis, use of, 27
- Hemoglobin molecule, CLIA-waived POC tests based on structural differences in, 57
- Hemoglobin S disease, hemoglobin electrophoresis and, 27
- Hemoglobinopathy, definition and causes of, 368
- Hemoglobinuria, 217
- Hemolysis, drug-induced autoimmune type, 366–367
- Hemolytic anemia, definition and causes of, 366, 367t
- Hemolytic-uremic syndrome, 382
- Hemophilia A and B, definition of, 386
- Hemorrhagic disorders, coagulation tests to monitor, 381t
- Hemosiderin, definition of, 364
- Hemostasis
 laboratory tests to evaluate, 380–385
 physiology of clot formation and, 377–380
- Henderson-Hasselbalch physiologic approach to acid-base, 290
- Heparin-induced platelet activation assay, 383
- Heparin-induced thrombocytopenia (HIT)
 definition and incidence of, 382, 383t
 tests to diagnose, 383
- Hepatic cirrhosis, description of, 317
- Hepatic dysfunction, lab tests affected by, 13
- Hepatic encephalopathy, 325, 335b
- Hepatitis
 definition, types, causes, diagnosis, of, 323, 324f
 laboratory diagnosis of acute, 336b
- Hepatitis A virus (HAV)
 symptoms, persons at risk, tests for, 326–327, 326t, 327f
 vaccine for, 327
- Hepatitis B virus (HBV)
 serological markers and tests for, 328t, 329f
 types, symptoms, persons at risk for, 326t, 327–330, 328f
 vaccine for, 330
- Hepatitis B core antigen (HBcAg), 327
- Hepatitis B extracellular antigen (HBeAg), 327
- Hepatitis B surface antigen (HBsAg), 327
- Hepatitis C virus (HCV)
 CLIA-waived POC test and public health efforts for, 60
 identifying candidates for CLIA-waived POC test for, 60
 laboratory diagnosis of, 336–337b
 names of CLIA-waived POC tests for, 61t
 number of Americans with, 60
 number of genotypes and subtypes of, 331
 RNA test for, 4
 symptoms and tests for, 326t, 330–331
 whole blood specimen for CLIA-waived POC test, 55
- Hepatitis D virus (HDV), symptoms and tests for, 326t, 331, 332f
- Hepatitis E virus (HEV), 326t, 331
- Hepatocellular injury, 323
- Hepatocellular liver disease, description of, 317, 319t
- Hepatotoxicity
 after acetaminophen overdose, 554f
 drug induced, 338b
- Hepcidin, iron transport by hepatic, 363
- HER-2, HER. *See* Human epidermal growth factor receptor 2
- Herbal products, in vitro interference by, 44
- Heritability, genetic basis of drug variability, 119
- Heroin, workplace accident with abuse of, 551b
- HEV. *See* Hepatitis E virus
- Hgb. *See* Hemoglobin
- HgbA1c
 enhanced pharmacy services with CPA/CDTM and POC test for, 56
 type 2 diabetes mellitus and, 57b
See also Glycosylated hemoglobin
- HHS. *See* Hyperosmolar hyperglycemia state
- High specificity test, examples of, 7
- High-density lipoproteins (HDLs)
 function and characteristics of, 150, 151t, 151f
 lipid panel component and values for, 156
 protect against atherosclerosis, 150
- High-level aminoglycoside resistance (HLAR), 419
- High-performance liquid chromatography (HPLC), components and use of, 25t, 30, 31f
- High-pressure liquid chromatography (HPLC), drugs interfere with, 44
- Hirsutism, definition, causes, laboratory findings, 611–612, 612t
- Histology, another name for image cytometry, 36
- HIT. *See* Heparin-induced thrombocytopenia
- HIV. *See* Human immunodeficiency virus
- HLA. *See* Human leukocyte antigen
- HLAR. *See* High-level aminoglycoside resistance
- Hodgkin lymphoma, 374
- Home testing, definition, advantages/disadvantages of, 15
- Home-testing kits, types of and list of FDA approved, 15
- Homeostasis, types of, 238–240
- Homeostatic mechanisms, water and sodium regulation, 230–232, 231f
- Hospital-acquired pneumonia (HAP), 411b, 433
- HPLC. *See* High-performance liquid chromatography
- HPV. *See* Human papillomavirus
- Human chorionic gonadotropin (hCG, HCG)
 definition and normal range of, 519
 examples of diagnostic test, 8
 use as tumor marker, 515t
- Human epidermal growth factor (EGFR), definition of, 522
- Human epidermal growth factor receptor 2 (HER, HER-2)
 use of, 520
 personalized cancer treatment with tumor marker, 516t
- Human Genome Project, 40
- Human immunodeficiency virus (HIV)
 antibody/antigen screening test, 8
 antibody tests for, 476–477
 description and serotypes of, 474
 identifying candidates for CLIA-waived POC test, 62
 laboratory tests for, 474–480, 477f
 names of CLIA-waived POC tests for, 61t
 number of American with, 62
 oral mucosal transudate specimen for CLIA-waived POC test, 55
 performance characteristics of CLIA-waived POC test for, 61t, 62
 pre-exposure prophylaxis testing for, 476b
 structure of, 28f
 viral load test, 479
 whole blood specimen for CLIA-waived POC test, 55
- Human leukocyte antigen (HLA), drug-induced adverse events and, 131

- Human leukocyte antigen (HLA-B27), definition and test for, 499
- Human Metabolome Database Project, description of, 40
- Human papillomavirus, screening test for, 8
- Hyperalbuminemia, 317–318
- Hyperandrogenism, definition and causes of, 610
- Hyperbilirubinemia
causes of indirect and direct, 322–323, 323*t*
definition of, 594
- Hypercalcemia
causes and symptoms of, 250–251
definition and causes in pediatrics, 584
- Hyperchloremia, causes of, 243–244
- Hypercortisolism, steroid-induced, 187*b*
- Hypercupremia, definition and causes, 256
- Hyperglycemia
definition of, 165–166
diagnosis, categories, therapy goals for, 172
- Hyperkalemia
definition and causes in pediatrics, 581–582
definition, causes, symptoms of, 241–242, 242*t*, 243*b*
- Hyperlipidemia
CLIA-waived POC test for detection/management of, 56
definition of, 58
- Hypermagnesemia
definition and causes in pediatrics, 587
definition, causes, symptoms of, 245, 245*t*
- Hyponatremia
after resection of pituitary tumor, 238*b*
definition and causes in pediatrics, 580
definition and symptoms of, 237
description of, 220
- Hyperosmolar hyperglycemia state (HHS), diabetes and, 175, 176*b*
- Hyperparathyroidism, definition and causes in pediatrics, 584
- Hyperphosphatemia
definition and causes in pediatrics, 586
definition and causes of, 253
- Hyperprolactinemia, definition and causes of, 607
- Hyperthyroidism
classification by etiology, 179*t*
laboratory tests for, 179*t*
patient with, 184*b*
- Hypertriglyceridemia, 155*b*
- Hyperuricemia, definition and laboratory tests for, 508–509, 510*b*
- Hyperzincemia, definition of, 257
- Hypoalbuminemia, definition of, 277–278, 317
- Hypocalcemia
definition and causes in pediatrics, 582–584
definition and causes of, 249
- Hypochloremia, causes of, 243
- Hypocupremia, definition, causes, and symptoms of, 255
- Hypoglycemia
blood glucose range for, 172, 175
classification of, 175
release of hormones in, 165
- Hypogonadism
comparison of menopause (women) and late-onset (male), 628*t*
definition, types, and causes of, 625–628, 627*t*
hormonal changes in male, 626
hormonal changes with late-onset, 627
- Hypokalemia
definition and causes in pediatrics, 581
definition, causes, symptoms of, 240–241, 240*t*
- Hypolipemic medications, effects on lipoproteins of various, 159–160, 159*t*
- Hypomagnesemia
definition and causes in pediatrics, 586–587
definition and causes of, 245
- Hyponatremia
definition and causes in pediatrics, 578–580, 579*b*
definition and symptoms of, 234–235, 234*t*
description of, 219
drugs that cause, 233*t*
symptoms and diagnosis of, 236*b*
- Hypoparathyroidism
causes of, 250
definition and causes in pediatrics, 583
- Hypophosphatemia
definition and causes in pediatrics, 584–586
definition and causes of, 252–253
- Hypothalamic-pituitary-ovarian axis, 602*f*
- Hypothalamic-pituitary-thyroid axis, 177*f*, 186
- Hypothalamus
releasing hormone from, 166*f*
thyroid-releasing hormone (TRH) from, 177*f*
- Hypothyroidism
case of possible, 185*b*
cause, classification, symptoms of, 178, 178*t*
definition and causes in women of, 607
laboratory tests for, 179*t*
- Hypouricemia, definition of, 509
- Hypovolemia, lab tests affected by, 13
- Hypoalbuminemia, definition and causes of, 256–257, 257*t*, 258*t*
- I
I-Iothalamate, urine clearance of, 202
- IA-2A. *See* Insulinoma-associated-2 autoantibodies
- IAA. *See* Insulin autoantibodies
- IAT. *See* Indirect antiglobulin test
- IBW. *See* Ideal body weight
- ICA. *See* Islet cell cytoplasmic autoantibodies
- ICD. *See* International Classification of Diseases
- ICI. *See* Intracavernosal injection
- ICW. *See* Intracellular water
- Ideal body weight (IBW), creatinine clearance and, 206
- Idiopathic thrombocytopenic purpura (ITP), 381*t*
- IDLs. *See* Intermediate-density lipoproteins
- IDMS. *See* Isotope dilution mass spectrometry
- IDSA. *See* Infectious Diseases Society of America
- IEF. *See* Isoelectric focusing
- IFE. *See* Immunofixation electrophoresis
- IFG. *See* Impaired fasting glucose
- IgE. *See* Immunoglobulin E
- IGNITE. *See* Implementing GeNomics In PracTice
- IGT. *See* Impaired glucose tolerance
- IHC. *See* Immunohistochemistry
- IIEF. *See* International Index of Erectile Dysfunction
- ILE. *See* Intravenous lipid emulsion therapy
- Illicit drug use, number of Americans reporting, 543, 544*t*
- IM-ADR. *See* Immune-mediated adverse drug reaction, 131
- Image cytometry, components and uses of, 36–37
- Immune-mediated adverse drug reaction (IM-ADR), HLA associated, 131
- Immunoassay
competitive, 22
description of HgA1c test using, 57
drug concentration measurement done in clinic office by, 75
heterogenous and homogeneous categories of, 31
principles, detection methods, use for, 30–34
- Immunofixation electrophoresis (IFE)
drugs that affect, 13
use of, 27
- Immunoglobulin antibodies, serological tests show, 56
- Immunoglobulin E (IgE), drugs that affect, 13

- Immunoglobulins
 classes of, 492
 definition, structure, and physiology of, 491–492
 function of fraction crystallizable (Fn) portion, 492
- Immunohistochemistry (IHC), measurement of proteins by, 520
- Immunosuppressant drugs, 84–85*t*, 105–107
- Immunosuppressant pharmacogenetics, TPMT phenotyping and, 127*b*
- Impaired fasting glucose (IFG), 168
- Impaired glucose tolerance (IGT), 168
- Implementing GeNomics In PracTicE, Pragmatic Clinical Trials Network, 123
- In situ hybridization, image cytometry and, 37
- In vitro drug interference
 definition, examples, reasons for, 43–44
 incidence of with new lab methods, 44–45
 substances in test tubes cause, 44
- In vivo drug interference
 definition, examples, reasons for, 43
 incidence of, 44–45
 simultaneous in vitro drug interference and, 44
- Inactive ingredients, in vitro interference by, 44
- Indicator electrode, 24
- Indifference, definition of, 417
- Indirect agglutination, description and uses of, 32
- Indirect antiglobulin test (IAT), 13, 366
- Indirect bilirubin
 definition of, 4
 normal range of unconjugated/insoluble, 321–322, 322*f*
- Indirect Coombs test, 13, 366
- Indirect lateral flow immunoassay, CLIA-waived POC and FDA approved for HCV, 60, 61*t*
- Infant, definition of age group, 574*t*
- Infection
 acute phase reactants and, 438–439
 assessing sterile body fluids for, 438, 438*t*, 439*t*
 common pathogens by site of, 410*t*
 definition, symptoms, and laboratory/radiologic signs of, 409, 409*t*
- Infectious diseases
 CLIA-waived POC tests diagnose, 53
 CLIA-waived POC tests qualitative for, 53
 concern of overtesting for, 70
 ELISA detects immunoglobulins in viral, 56
 pharmacy degree programs do not include POC tests, 69–70
- types of CLIA-waived POC tests for, 55–56
- types of specimens for CLIA-waived POC tests for, 55–56
- Infectious Diseases Society of America (IDSA), POC test for influenza recommended by, 64
- Infertility
 definition, incidence of, cause of female, 613–614, 615*t*
 history and physical exam in female, 614*t*
 male factors in female, 614*b*
- Inflammation
 as component of malnutrition, 276
 effect on serum albumin and prealbumin, 278
- Influenza A and B
 annual number of Americans with, 63
 CLIA-waived POC tests for, 55
 identifying candidates for CLIA-waived POC test, 63
 performance characteristics of CLIA-waived POC tests, 63, 65*t*
 physician-pharmacist management model from CDC for, 63
- Informatics, laboratory automation and, 20–21
- Infradian rhythm, description of, 12
- Inhibitor quotient (IQ), 101
- Innocent bystander, immune complex of antibodies and RBCs, 367
- Inotropic effect, management of heart failure with digoxin's, 102
- INR. *See* International Normalized Ratio
- Insensible water loss, definition and comparison by body weight, 578
- Inspiratory capacity, definition of lung, 310
- Inspiratory reserve volume (IRV), definition of, 310, 310*f*
- Insulin, β cells of pancreas secrete, 165
- Insulin autoantibodies (IAA), 167
- Insulin clearance, chronic kidney disease and, 202
- Insulinoma, 167
- Insulinoma-associated-2 autoantibodies (IA-2A), test, 167
- Interferences
 definition and examples of for qualitative and quantitative tests, 54
 manufacturer's package insert gives information on, 54
- Intermediate-density lipoproteins (IDLs), function and characteristics of, 150, 150*f*, 151*t*
- International Classification of Diseases (ICD), codes for malnutrition in, 275, 276*t*
- International Code of Botanical Nomenclature for Fungi, 445
- International Committee on Taxonomy of Viruses (ICTV), 461
- International Index of Erectile Dysfunction (IIEF), domains and score for, 634*t*
- International normalized ratio (INR)
 calculation of, 388
 definition and normal range of, 387
 monitors anticoagulation therapy, 385
 normal range and use of, 318
- International Prostate Symptom Score (IPSS), 636–637
- International Sensitivity Index (ISI), definition of, 9, 388
- International Society for the Study of the Aging Male, 629
- International Society of Andrology, 629
- International System of Units (SI), 7, 229
- Internet, laboratory/healthcare system use of, 21
- Intersystem crossing, 22
- Intracavernosal injection (ICI) test, 633*t*
- Intracellular water (ICW), pediatric versus adult, 576–577, 577*f*
- Intrahepatic cholestasis, definition of, 319
- Intrauterine drug exposure, 556
- Intravenous lipid emulsion (ILE) therapy, rescue therapy for toxicity, 552
- Invasive test, noninvasive test versus, 4
- Ion detector, component of mass spectrometer, 35
- Ion trap analyzer, 34–35
- Ionization methods, mass spectrometry and, 34
- Ion-selective electrodes (ISEs)
 advantage over flame photometry for, 24
 components, advantage, uses of, 24, 25*t*
- Ion-selective glass membrane electrodes, 24, 25*f*
- IPSS. *See* International Prostate Symptom Score
- IQ. *See* Inhibitor quotient
- Iron, storage and recycling of body, 365*f*
- Iron deficiency, causes of, 363–364
- IRV. *See* Inspiratory reserve volume
- ISEs. *See* Ion-selective electrodes
- ISI. *See* International Sensitivity Index
- Islet cell cytoplasmic autoantibodies (ICA) test, 167
- Isoelectric focusing (IEF), electrophoresis technique of, 26
- Isoenzymes, cytochrome P450 (CYP450) family of, 12
- Isothermal amplification, 38
- Isothermal nucleic acid amplification method, CLIA-waived POC test for influenza A and B, 64
- Isotope dilution mass spectrometry (IDMS)
 definition, 204
 serum creatinine measured by, 587, 588
- ITP. *See* Idiopathic thrombocytopenic purpura

- J**
- Jaffe method, serum creatinine measured by, 44, 58f
- Jaundice
causes of icterus and, 322
Gilbert syndrome and, 335b
oral contraceptives cause, 334b
- JIA. *See* Juvenile idiopathic arthritis
- Jo-1 antibody (anti-Jo), 495–496
- Joint Commission, standards for nutritional screening/assessment, 275
- Junctional potential, redux potential versus, 24
- Juvenile idiopathic arthritis (JIA)
definition and laboratory tests for, 503–504
nonrheumatic tests for, 505
- K**
- KDIGO. *See* Kidney Disease Improving Global Outcomes
- KDOQI. *See* Kidney Disease Outcomes Quality Initiative
- Ketones
description and normal range for urine, 218
DKA and presence of blood and urine, 174
- Ketonuria, diabetes mellitus and, 174, 219b
- Kidney biopsy, example of diagnostic test, 8
- Kidney disease, medication safety and dosage adjustment in, 208
- Kidney Disease Improving Global Outcomes (KDIGO)
guidelines for CKD, 591
urine testing recommendations, 214
- Kidney Disease Outcomes Quality Initiative (KDOQI), guidelines for CKD, 207
- Kidney function
age groups and changes in, 578
assessment of, 202–205
exogenous and endogenous markers of, 202
- Kidney function tests, age-related differences in, 587–592
- Kidneys
anatomy and physiology of, 201–202, 232
retention and excretion of sodium/water by, 231–232
- Koch-Weser, variations in steady-state serum drug concentrations, 75
- KRas
description of, viral oncogene, 522
personalized cancer treatment with tumor marker, 516f
- Kwashiorkor, definition of, 275
- L**
- La/Sjögren syndrome B antibody (anti-La/SSB), test for, 495
- LABA. *See* Long-acting β_2 -agonist
- “Lab-on-a-chip,” microarray technology and, 40
- Laboratory, areas of a centralized laboratory, 20
- Laboratory information system (LIS), link to electronic medical records, 20
- Laboratory practices, policies and procedures for good, 67–69, 68f
- Laboratory tests
acute coronary syndrome (ACS), 140–142
adrenal disorders, 187–188
biologic rhythms affect, 12
calcium, 251t
definition of spurious result, 16
diabetes mellitus, 167, 168t, 169–170
disease diagnosis and role of, 19–20
factors that influence results of, 8–13, 9t, 10f
glucose control, 168–172
ketones in blood and urine, 174–175
lipids and lipoproteins, 153–156
noncentralized, 14–15
nutritional status, 275–281
OIG projected savings for Medicare, 20
pediatric reference ranges for, 575
performed with assays, 25t
purpose of, 3
questions to ask before ordering, 8
rationale for ordering, 7
reasons for errors in results of, 9
reproductive cycle and hormone, 602–605
result of isolated abnormal value versus series of, 15
screening versus diagnostic, 8, 8t
thyroid disease, 178–181, 179t
thyroid disorders and drug effects on, 183t
See Specific name of test
- Laboratory test-drug interactions, categories/examples of, 12–13
- Laboratory test results
guidelines for interpreting, 15–16
in vivo/in vitro drug interference with, 43
isolated abnormal value versus series of, 15
reasons for errors in of, 9
- Laboratory value, information needed to order/interpret, 78t
- Lactate dehydrogenase (LDH)
isoenzymes of, 4
pediatric and adult normal ranges, 593
timing of postmyocardial infarction level of, 11
- Lactic acidosis, classifications of, 292, 293t
- LADA. *See* Latent autoimmune diabetes mellitus
- Last menstrual period (LMP), 603
- Latent autoimmune diabetes mellitus (LADA), characteristics of, 167
- Latent tuberculosis infection (LTBI), skin testing for, 484
- Latex agglutination (LA) method, detection of fungi by, 458
- Latex agglutination immunoassay, advantages/disadvantages of, 32 32f
- LBW. *See* Lean body weight
- LDH. *See* Lactate dehydrogenase
- LDLs. *See* Low-density lipoproteins
- Lean body weight (LBW), creatinine clearance and, 206
- Left ventricular ejection fraction (LVEF), 142
- Legal issues, urine drug screens and serum drug concentrations, 556
- Leukemia, definition and types of, 372–374
- Leukocyte esterase, description and normal range for urine, 217
- Leukocytes (WBCs)
pediatric and adult normal ranges, 594
types of disorders of, 372
- Lexicomp, online drug database, 47, 49b
- Leydig cells, in testes, 625
- LFTs. *See* Liver function tests
- Lidocaine, therapeutic range and clinical considerations, 103
- Lifestyle modifications, effect on lipoprotein concentrations, 153
- Ligase chain reaction, 38
- Light, wavelength characteristics of, 21t
- Limit of detection, definition of, 53
- Linear potential sweep polarography, 26
- Lipase, description and normal range of, 340
- Lipid disorders, definition and causes of primary and secondary, 151
- Lipid level, effect of drugs on, 152
- Lipid metabolism, physiology of, 149–153
- Lipid panel/panel
no longer need fasting specimen, 154, 157b
other risk-enhancing factors to include in, 157–158
screening test for, 8
standard tests included in, 153
- Lipolysis, definition of, 165
- Lipoprotein lipase (LPL), function and characteristics of, 150, 150f
- Lipoproteins, characteristics, origins, major classes of, 150, 151t
- Liquid chromatography
confirm result of urine drug screen, 545
tandem mass spectrometry (LC-MS), 629
- Liquid ion-exchange membrane electrodes, 24
- LIS. *See* Laboratory information system

- Lithium, importance of sample timing with, 87
- Liver, anatomy and physiology of, 315, 316f
- Liver disease, classification of, 319t
- Liver enzymes, pediatric and adult normal ranges, 592
- Liver failure, acute, 337b
- Liver function tests (LFTs)
categories of, 316t, 317–318
age-related differences in, 592–594
abnormal, 334b
- LLN. *See* Lower limit of normal
- LMP. *See* Last menstrual period
- LMWH. *See* Low molecular weight heparin
- Loading dose, steady-state concentration with and without, 85f, 86
- Long-acting β_2 -agonist (LABA), 307
- Low molecular weight heparin (LMWH), 379–380
- Low-density lipoproteins (LDLs)
focus of dyslipidemia management, 150
function and characteristics of, 150, 150f, 151t
lipid panel component and values for, 156
- Lower limit of normal (LLN), 302, 304
- Lower respiratory tract, sputum specimen not used for CLIA-waived POC test, 55
- Lower urinary tract symptoms (LUTS), benign prostatic hypertrophy and, 636, 637b
- LPL. *See* Lipoprotein lipase
- LTBI. *See* Latent tuberculosis infection
- Lungs, anatomy and physiology of, 301
- Luteal phase, hormone levels during, 602
- Luteinizing hormone (LH)
definition of, 625
drugs affecting lab value of, 603t
pediatric and adult normal range, 603
pediatric and female normal range, 610t
- Luteinizing hormone-releasing hormone (LHRH), chemotherapy for prostate cancer, 629
- LUTS. *See* Lower urinary tract symptoms
- LVEF. *See* Left ventricular ejection fraction
- Lymphocyte count, not clinical marker for nutritional status, 280
- Lymphocytes, definition, types, function, and normal ranges for, 370–372
- Lymphoma, definition and types of, 374
- Lymphopenia, anemia and, 373b
- M**
- m/z ratio, description of, 34
- MAC. *See* Membrane attack complex; *Mycobacterium avium* complex
- Macroalbuminuria, 176
- Macroamylasemia, 340
- Macro-AST, definition of, 325
- Macrocyte, definition and causes of, 358
- Macrocytic anemia
drug-induced, 361t
types of, 361–363
- Macrocytic, megaloblastic anemia, 362
- Macrophages, definition and normal range for, 370
- Macroprolactinemia, definition of, 636
- Magnesium
description and normal range, 244–245
pediatric and adult normal ranges, 586
- Major histocompatibility complexes (MHC), 370
- MALDI. *See* Matrix-assisted laser desorption/ionization
- MALDI-TOF (matrix-assisted laser desorption-ionization time-of-flight)
- MALDI-TOF mass spectrometry (MS), identify fungi and bacteria by, 408, 447, 460–461
- Malnutrition
cardiac surgery and risk of, 282b
complications of, 275
definition of, 276
factors for increased risk of, 281t
phenotypic or etiologic criteria for, 281
- Manganese
deficiency and excess of, 258
description, physiology, normal range of, 257
- Mantoux test, for tuberculosis, 484–485
- Manufacturer's instructions, pharmacist must follow POC test's, 69
- Manufacturer's literature, performance characteristics of CLIA-waived POC test in, 53
- Marasmus, definition of, 275
- Mass analyzers, component in mass spectrometer, 34
- Mass spectrometer
Fourier transform, 35
time-of-flight, 35
- Mass spectrometry (MS)
gold standard for unknown substances, 41
ionization methods for, 34
principles, components, types of, 28, 34
types of mass analyzers for, 34
- Massachusetts Male Aging Survey, 628
- Matrix-assisted laser desorption/ionization (MALDI), 34
- Matrix-assisted laser desorption/ionization time of flight system (MALDI-TOF), 35
- MBC. *See* Minimum bactericidal concentration
- MCH. *See* Mean corpuscular hemoglobin
- MCHC. *See* Mean corpuscular hemoglobin concentration
- MCTD. *See* Mixed connective tissue disease
- MCV. *See* Mean corpuscular volume
- MDRD. *See* Modification in Diet of Renal Disease
- MDx. *See* Molecular diagnostics
- Mean corpuscular hemoglobin (MCH), definition and normal range of, 356t, 358
- Mean corpuscular hemoglobin concentration (MCHC), definition and normal range of, 356t, 358
- Mean corpuscular volume (MCV), definition and normal range of, 356t
- Mean k value, by age group, 590
- Mean platelet volume (MPV), definition and normal range of, 356t, 384
- Mechanization, definition and characteristics of lab test, 19–20
- Medical mycology, definition of, 445
- Medicare laboratory test reimbursement, cost of, 20
- Medication safety, kidney disease and, 208, 209–210t
- Melanoma, BRAF mutation with, 130–131
- Membrane attack complex (MAC), 497
- Membrane osmometer, components of, 23–24
- Menkes syndrome, definition of, 255
- Menstrual cycle, hormone levels during, 601, 602f
- Metabolic acidosis
cause of, 292, 293t
chronic kidney disease and, 250
classified by anion gap, 292, 293t
compensatory response to, 292t
- Metabolic alkalosis
cause of, 292–293, 294t
chloride resistant versus chloride responsive, 292, 294, 294t
compensatory response to, 292t
diuretic therapy as cause of, 294
- Metabolic syndrome, characteristics of, 155
- Metabolite, therapeutic range affected by active drug, 80, 81f
- Metabolites, therapeutic response or toxicity, affected by active, 90
- Metabolizer status, levels of, 123–124
- Metabolomics
definition of, 38–40
personalized medicine and, 19
- Methadone treatment program, 558
- Methicillin-resistant *Staphylococcus aureus*, tests to detect, 97–98, 419–420
- Methotrexate, importance of sample timing with, 87–88
- Methyldopa, fructosamine false test result caused by, 170
- Mexiletine, therapeutic range and clinical considerations, 103
- MHA-TP. *See* Microhemagglutination *T pallidum*
- MHT. *See* Modified Hodge test

- MIC. *See* Minimum inhibitory concentration
- Michaelis-Menton, drug elimination, 88
- Microalbuminuria
CLIA-waived POC test for, 60
screening tests for, 175
- Microbial identification systems, laboratory, 20
- Microcytic anemia, types of, 363–365
- Microhemagglutination *T pallidum* (MHA-TP) test, 437
- Micromedex Solutions, online drug database, 47, 49*b*
- Microorganisms, PCR better than cultures to identify, 38
- Micro-satellite instability (MSI), definition of, 523
- Milk-alkali syndrome (Burnett syndrome), 250
- Minerals, recommended dietary intake of, 230*t*
- Mini Nutritional Assessment, 281
- Minimum bactericidal concentration (MBC)
CLSI standardization of method for, 417
definition of, 414
- Minimum inhibitory concentration (MIC)
antibiotic and bacteria breakpoints for, 412–414
bactericidal activity and, 96
- Mismatch repair (MMR) system, genomic alterations and, 523
- Mixed connective tissue disease (MCTD), presence of ANA and RF in, 492
- MMR. *See* Mismatch repair
- moAbs. *See* Monoclonal antibodies
- Model for End-stage Liver Disease score, 317
- Modification of Diet in Renal Disease (MDRD)
description of, 202
equation for creatinine clearance, 205*b*
equation for glomerular filtration rate, 207
- Modified Centor Criteria Score, GAS diagnosed with, 64, 66*b*, 67*t*
- Modified Hodge test (MHT), 418
- Molds, genus and species names of medically important, 446*t*
- Molecular absorption spectrophotometer, nephelometry and EIA, 21–23
- Molecular diagnostics (MDx)
automation and types of, 37–38
components and uses of, 29
- Molecular emission spectrophotometry, also known as fluorometry, 22
- Molecular tests
description and technology of, 55, 56
drug disposition-related, 123–129
drug target-related, 129–131
- Monoamine oxidase inhibitors, therapeutic range, 107
- Monochromator
excitation and emission, 22
types of, 21, 21*f*
- Monoclonal antibodies (moAbs), development of, 31
- Monoclonal antibody drugs, lab test results and effect of, 13
- Monocytes, definition, function, and normal range of, 370
- mOsm. *See* Serum osmolality
- Mosteller formula, equation for body surface area, 589
- Motor vehicle accident, acid-base disorder after, 293*b*
- MPV. *See* Mean platelet volume
- MRP. *See* Multidrug resistant gene associated protein
- MRSA. *See* Methicillin-resistant *Staphylococcus aureus*
- MS. *See* Mass spectrometry
- MSI. *See* Micro-satellite instability
- MUDPILES, mnemonic for causes of anion gap acidosis, 292
- Multidrug resistant gene associated proteins (MRP1, MRP2, MRP3), 12
- Multiplexed point-of-care (xPOCT) testing, definition of, 14
- Multistix, types of tests with urine dipstick, 216*t*
- Mycobacteria
description, groups, and identification of, 481–483
infections associated with, 482*t*
speciation of, 476*b*
susceptibility testing guidelines for, 483
- Mycobacterium avium* complex (MAC), acid-fast stain for, 4
- Myelodysplastic anemia, 372
- Myeloproliferative disorders, types of, 372–373
- Myocardial infarction (MI)
complications from, 140
diagnosis by ECG and biomarkers, 140
timing of testing enzyme levels after, 9, 11
- N**
- NAAT. *See* Nucleic acid amplification test
- NAFLD. *See* Nonalcoholic fatty liver disease
- Nanobiosensor-based technology, future in POC testing, 16
- Nanoequivalent, unit of measure for hydrogen ions, 287
- Nanometer (nm), measurement of wavelength of light, 21, 21*t*
- Nanoscale devices, size of, 40
- Nanotechnology, description of, 40
- Narcotic drugs, lab tests affected by, 13
- NASH. *See* Nonalcoholic steatohepatitis
- National Academy of Clinical Biochemistry (NACB), phenotyping guidelines, 120, 132
- National Center for Biotechnology Information (NCBI), SNP database, 124
- National Cholesterol Education Program, goal of, 58
- National Comprehensive Cancer Network (NCCN), guidelines for prostate cancer, 644
- National Glycohemoglobin Standardization program (NGSP)
manufacturer certification by, 57
standardized HgbA1c test results, 56–57, 170
- National Health and Nutrition Examination Survey (NHANES III), 6, 302
- National Highway Traffic and Safety Administration, list of breath alcohol test devices, 554
- National Institutes of Health (NIH)
categories/types of prostatitis, 648, 649*t*
Pharmacogenomics Knowledge Database, 122
- National Kidney Disease Education Program (NKDEP), SCr measurement and, 203, 588–589
- National Kidney Foundation (NKF), clinical practice guidelines for CKD, 207
- National Reference System for Cholesterol (NRS/CHOL), test methods for cholesterol, 58–59
- National Survey on Drug Use and Health (NSDUH), 543
- Natriuretic peptides
cardiac specific B-type, 143
water/sodium regulation by, 231, 233–234
- Natural killer (NK) cells, definition and function of, 372
- NCBI. *See* National Center for Biotechnology Information
- NCCN. *See* National Comprehensive Cancer Network
- Necrokinetics, definition of, 556
- Negative predictive value (NPV)
definition of, 5, 53
dependent on population tested/disease prevalence, 54
qualitative CLIA-waived POC test and, 54
- Neisseria gonorrhoeae*, gonorrhea caused by, 435
- Neonate, definition of age group, 574*t*
- Nephelometry
definition, uses, and advantages of, 23
molecular absorption spectrophotometer used with, 21, 23
- Nephrogenic diabetes insipidus, 189
- Nephrology Practice and Research Network, algorithm of, 208
- Nephrotoxicity, vancomycin, 97

- Nernst equation, 24
- Neutropenia, definition of absolute, 372
- Neutrophils
 definition, types, function, and normal range of, 369, 369*t*
 other names for, 369, 369*t*
- New York Heart Association Classification, of heart failure symptoms, 143
- Newborn baby, toxicological testing of, 556
- Next-generation sequencing (NGS), DNA sequencing method of, 132, 523
- NGS. *See* Next-generation sequencing
- NGSP. *See* National Glycohemoglobin Standardization Program
- NHANES III. *See* National Health and Nutrition Examination Survey
- Nicotine detection test, 60
- NIH. *See* National Institutes of Health
- Nitrite, description and normal range for urine, 218
- Nitrogen balance, description and equation for, 280
- NK. *See* Natural killer cells
- NKF. *See* National Kidney Foundation
- NMIBC. *See* Carcinoma, nonmuscle-invasive
- NNRTIs. *See* Non-nucleoside reverse-transcriptase inhibitors
- NNS. *See* Number needed to screen
- Nocturnal penile tumescence and rigidity test, 633*t*
- Nonalcoholic fatty liver disease (NAFLD), 319
- Nonalcoholic steatohepatitis (NASH), 323–324, 338*b*
- Non-high-density lipoprotein cholesterol, lipid panel component and values for, 156–157
- Non-Hodgkin lymphoma, 374
- Nonion gap, causes of, 292, 293*t*
- Nonlinearity, definition of, 88
- Non-nucleoside reverse-transcriptase inhibitors (NNRTIs), 101
- Nonradioactive immunoassay, 629
- Non-small cell lung (NSCL) cancer, EGFR and, 522
- Non-small-cell lung cancer (NSCLC), EGFR mutation with, 130
- Non-ST-segment myocardial infarction (NSTEMI), 140
- Normal flora, definition of, 408
- Normalization of measured total concentration, use of equations and literature to, 89–90
- Normochromic, normocytic anemia, causes of, 365
- Northern blot electrophoresis, methods and use for, 27
- NPV. *See* Negative predictive value
- NRS/CHOL. *See* National Reference System for Cholesterol
- NSCL. *See* Non-small cell lung cancer
- NSCLC. *See* Non-small-cell lung cancer
- NSTEMI. *See* Non-ST-segment elevation myocardial infarction
- Nuclear/cytoplasmic antigens, characteristics of antibodies to, 493–494*t*
- Nucleic acid amplification, types of, 38
- Nucleic acid amplification test (NAAT), fungi and viruses identified by, 435, 447, 472
- Nucleic acid methods, detection of viruses by, 472
- Nucleic acid sequence-based amplification, 38
- Nudix hydrolase 15 (*NUDT15*) enzyme, 128
- Number needed to screen (NNS), definition of, 8
- Nutritional assessment, purpose of, 281
- Nutritional status
 Joint Commission standards for, 275
 laboratory tests for, 275–281
- O**
- OATP. *See* Organic anion transporting peptide
- Obstructive and restrictive lung diseases, types of, 302, 303*t*
- Occupational Safety and Health Administration (OSHA), work place safety standards, 68
- Occupational Safety and Health Administration, for HPLC, 30
- Office of In Vitro Diagnostics and Radiological Health, FDA, 15
- Office of the Inspector General (OIG), cost of Medicare lab tests, 20
- OGTT. *See* Oral glucose tolerance test
- OIG. *See* Office of the Inspector General
- OIR. *See* Office of In Vitro Diagnostics and Radiological Health
- “One dose fits all” strategy, avoiding, 119
- Opioid analgesics, monitoring chronic therapy with, 559*b*
- Oral glucose tolerance test (OGTT), types of, 168, 169
- Oral mucosal transudate, CLIA-waived POC test for HIV, 55
- Organic anion transporting peptide (OATP), 12
- OSHA. *See* Occupational Safety and Health Administration
- Osmolality
 definition of osmolarity versus, 230
 definition of, 23
 formula for serum, 174
- Osmolarity, definition of, 23
- Osmometers
 colloid osmotic pressure or membrane, 23–24
 types and uses for, 23
- Osmometry, principles of, 23
- Osmoreceptors, function of, 231
- Osteoarthritis (OA), definition and laboratory tests for, 503
- Ototoxicity, vancomycin toxicity, 97
- Outpatient pharmacy, common CLIA-waived tests in, 56
- Ovarian failure, definition and causes of, 607–608
- Overweight, diabetes testing for asymptomatic persons who are, 168
- Ovulation, hormone levels during, 601–602
- Oxacillin-salt agar screening test, 419
- Oxygen delivery (DO_2), definition and equation for, 289
- Oxygen saturation, definition of, 288
- Oxyhemoglobin dissociation curve, definition and factors that affect, 288, 288*f*
- P**
- P-glycoprotein (P-gp), drug transporter, 12
- p24, first viral protein detected after HIV infection, 62
- p24 antigen test, identification of HIV with, 479
- pAbs. *See* Polyclonal antibodies
- PaCO₂. *See* Arterial partial pressure of carbon dioxide
- PAE. *See* Postantibiotic effect
- Pancreas, anatomy and physiology of, 316
- Pancreatitis
 causes, symptoms, and tests for, 333, 339–340, 341*b*
 drugs that cause, 339*t*
 malnutrition risk for acute, 283*b*
- PaO₂. *See* Arterial partial pressure of oxygen
- Papanicolaou smear, as a screening test, 8
- Parasites, laboratory tests for detecting, 427*t*
- Parathyroid hormone (PTH), effect on calcium of, 248, 249*f*
- Passive (or particle) agglutination, also known as *indirect agglutination*, 32
- Pathogens
 sites of infection by common, 410*t*
 tests to detect, 55
- Patient access portal, lab data accessed via, 21
- Patient self-management (PSM), for INR, 395
- Patient self-testing (PST), for INR, 395
- Patient-centered care, pharmacist’s role in wellness and, 51
- Patient-specific factors, laboratory test results influenced by, 9
- PBC. *See* Primary biliary cholangitis
- PBP. *See* Penicillin-binding protein
- PCA3 assay score, definition of, 648
- PCOS. *See* Polycystic ovarian syndrome
- PCR. *See* Polymerase chain reaction
- PD-L1. *See* Programmed death-ligand 1

- Peak, definition and reasons to use drug level, 86–87
- Peak expiratory flow (PEF), definition of, 307
- Peak expiratory flow rate (PEFR), 307
- Peak flow meter, how to use, 307, 309
- Peak time, package insert gives, for different formations of a drug, 88
- Pediatric body composition, fluid compartments and, 576
- Pediatric clinical presentation, adult symptoms different from, 576
- Pediatric patients
age and variations in heart/respiratory rate and blood pressure, 573–574
physiologic differences that influence lab data, 573
- Pediatric reference ranges, laboratory test and results, 11, 575
- PEF. *See* Peak expiratory flow
- PEFR. *See* Peak expiratory flow rate
- Pelvic inflammatory disease (PID), 435
- Penicillin-binding protein (PBP), 419
- Penile duplex ultrasonography, 633*t*
- Performance characteristics, manufacturer's literature has CLIA-waived POC test, 53
- Performance-enhancing drugs, detection of athletic, 558, 558*t*
- Perfusion (P), definition of, 301–302
- Perimenopause, symptoms of, 608–609, 609*b*
- Perinuclear antineutrophil cytoplasmic antibody (pANCA), test for, 496
- Periodic acid-Schiff stain, for identification of fungi, 454, 455*t*
- Pernicious anemia, causes of, 362–363
- Personalized medicine, advances in genetics and, 19
- PF ratio, definition and normal value of, 288
- PF4 platelet test, definition and normal range of, 385
- PFGE. *See* Pulsed-field electrophoresis
- PFT. *See* Pulmonary function test
- PGI₂. *See* Prostacyclin
- PGs. *See* Prostaglandins
- PGx. *See* Pharmacogenetic (test)
- pH
acidemia and alkalemia refer to abnormal, 287
consequences of abnormal, 288
description and normal range for urine, 214–215
drug alters specimen, 44
factors affecting urine, 218*t*
normal range of, 287
- pH meter, use of ISE in, 25*f*
- Pharmacist
authorized by Department of Health and Human Services to give COVID-19 POC tests, 66
- CDC says training needed on CLIA-waived POC tests for, 52*t*, 68
- CLIA-waived POC test for ASCVD used by, 58
- CPA/CDTM agreement for enhanced pharmacy services by, 56, 59
- role change from product focused to patient-oriented, 51
- therapeutic drug monitoring and importance of, 75
- Pharmacodynamics, definition of, 79
- Pharmacogene Variation Consortium, nomenclature for polymorphisms, 122
- Pharmacogenetic genotyping, limitations of cost and time, 132
- Pharmacogenetic test and testing (PGx)
risks and ethical issues for, 122
types of, 120*t*
versus disease genetic testing, 120
- Pharmacogenetics
cardiovascular, 126*b*
codeine, 125*b*
description and goals of, 119 120*t*
personalized/precision medicine and, 122
resources for, 122, 123*t*
- Pharmacogenomic information, online resources for, 123
- Pharmacogenomics
clinical implementation of, 132
description and key terms, 119, 120*t*
- Pharmacogenomics Knowledge Database (PharmGKB), description of, 122
- Pharmacokinetics
circadian rhythm affects
aminoglycoside, 12
description of, 123
laboratory test and change in physiology and, 11
racemic mixture of enantiomers and effect on, 81
- Phenotype
definition of, 120*t*
standardized by CPIC, 123
- Phenylalanine hydroxylase deficiency, test for, 6
- Phenylketonuria (PKU), test for, 6, 7
- Phenytoin
effect on T₃ and T₄, 181
methods for dose adjustments for, 88
unbound serum concentration of, 89*b*
- PHI. *See* Prostate Health Index
- Philadelphia chromosome, BCR-ABL fusion gene, 521
- Phosphate, description, physiology, normal range of, 251
- Phosphate buffer system, intra- and extracellular buffer, 290
- Phospholipids, function of, 149
- Phosphorescence, description and components of, 22
- Phosphorus, pediatric and adult normal ranges, 584
- Photodetector, 22
- Photoluminescence, techniques for, 22
- Photometry, definition/types of instruments, 21–23
- Photomultiplier tube, 21, 21*f*
- Physicians' Desk Reference*, description of, 47
- PI. *See* Protease inhibitors
- PID. *See* Pelvic inflammatory disease
- Pituitary gland
stimulating/inhibitory hormone from anterior, 166*f*
thyroid-stimulating hormone (TSH) from anterior, 177, 177*f*
- PKU. *See* Phenylketonuria
- Plasma, definition and components of, 7
- Plasminogen, factors that activate or inhibit, 381*f*
- Platelet aggregation, definition and tests for, 385
- Platelet count
definition and normal range of, 356*t*, 359, 380, 382
pediatric and adult normal ranges, 596
- Platelet factor 3 (PF), 378
- Platelet function, drugs that cause abnormal, 385*t*
- Platelet function test, diseases associated with increased and decreased, 384, 384*t*
- Platelet survival time, test of, 385
- Platelets
definition and function of, 377–378
relationship between clotting cascade and, 378*f*
types of tests for, 380–385
- Pleural fluid, interpretation of findings of, 438*t*
- Pluripotential cells, definition and CD34 surface marker on, 356
- PMA. *See* Postmenstrual age
- PMN. *See* Neutrophil (polymorphonuclear), 369
- PNA. *See* Postnatal age
- PNA-FISH, nonamplified bacterial identification method, 408
- POC (Point-of-care)
- POCT. *See* Point-of-care testing
- Point-of-care test and testing (POCT)
advantages/disadvantages of, 14
alternative names and apps for, 14
breath alcohol determination, 556
coagulation tests available as, 394
future trends in, 16
limitations of, 69
miniaturization of analyzers for, 21
personnel performing and location of, 14
urine drug screens and, 544
waived for pharmacists under CLIA-88, 51

- Poison Control Center
 categories of poison exposure reported to, 545*t*
 information from clinical toxicologists in, 559
- Poisoning
 number of annual unintentional and intentional, 543
 SAMHSA or DEA website information on, 559
- Polarography, types of, 26
- Policies and procedures, before offering CLIA-waived POC tests, 68
- Polyclonal antibodies (pAbs), early immunoassays used, 31
- Polycystic ovary syndrome (PCOS), definition, symptoms, diagnosis of, 603, 609–610, 611*t*
- Polymerase chain reaction (PCR)
 advantages/disadvantages of, 29, 38
 description, steps of cycle, use of, 25*t*, 38, 39*f*
- Polymorphisms
 factors in significance of drug metabolism, 129
 Pharmacogene Variation Consortium nomenclature for, 122
- Population pharmacokinetic dosage adjustment method, 88
- Positive predictive value (PPV)
 definition of, 53
 dependent on population tested/disease prevalence, 54
 qualitative CLIA-waived POC test and, 54
- Postantibiotic effect (PAC), aminoglycosides, 97
- Postmenopausal women, steroid hormone levels in, 610*t*
- Postmenstrual age (PMA), definition of, 574*t*
- Postnatal age (PNA), definition of, 574*t*
- Postoophorectomy women, steroid hormone levels in, 610*t*
- Postprandial glucose (PPG), two-hour readings for, 172
- Posture, lab tests affected by, 13
- Postvoid residual urine volume, normal range, 638–639
- Potassium
 description and normal range, 237–238
 description and normal range for urine, 220
 pediatric and adult normal ranges, 580–581
See also Serum potassium
- Potentiometer, use of, 24
- Potentiometry, description and use of, 24
- PPD. *See* Purified protein derivative
- PPG. *See* Postprandial glucose
- PPIs. *See* Proton pump inhibitors
- Prealbumin (transthyretin), definition, normal range, and uses of, 318
- Precision
 characterized by standard deviation for quantitative CLIA-waived POC tests, 53
 CLIA-waived POC test and definition of, 53
 definition of, 3
- Precision medicine, pharmacogenetics and personalized, 122
- Precursor blood cells, developmental stages of, 357
- Predictive linear regression equation, 90
- Predictive value, definition and use of, 4, 4*t*
- Pregnancy
 diabetes insipidus in, 189
 gestational diabetes mellitus (GDM), 166, 167
 lab tests affected by, 13
- Premature neonate, definition of age group, 574*t*
- Premenopausal women, steroid hormone levels in, 610*t*
- Prevalence, predictive value derived from disease, 4, 4*t*
- Primary biliary cholangitis (PBC), symptoms and tests for, 331
- Primary care physicians, pharmacists and CLIA-waived testing due to shortage of, 70
- Primary care provider, value of screening lipid profile by, 157*b*, 158*b*
- Primary medical literature, description and examples of, 49
- Pro Time test. *See* Prothrombin time
- Procainamide, therapeutic range and clinical considerations, 103–104
- Productivity, automation as driver in clinical laboratory, 20
- Profile
 benefits and drawbacks of laboratory test, 8
 definition and examples of laboratory test, 8
- Progesterone
 drugs affecting lab value of, 604*t*
 pediatric and adult normal ranges, 604
 pediatric and female reproductive normal range, 610*t*
- Progesterone challenge test, estrogen status and, 610
- Progesterone receptor (PR)
 personalized cancer treatment with tumor maker, 516*t*
 response to treatment predicted by, 513
- Progesterone receptor (PR) assay, use of, 520
- Programmed death-ligand 1 (PD-L1), description of, 523
- Proinsulin, precursor of insulin, 167
- Prolactin
 adult men normal range, 634
 conditions associated with increased/decreased, 635*t*
 drugs affecting lab value of, 605*t*
 pediatric and adult normal ranges, 604
- Prostacyclin (PGI₂), platelet aggregation inhibited by, 378
- Prostaglandins (PGs), platelet function and role of, 378
- Prostate cancer
 clinical tests to stage, 639–640, 639*t*
 definition, symptoms, causes of, 639–640
 free PSA and probability of, 647*t*
 National Comprehensive Cancer Network risk-stratification guideline for, 644
 professional organizations screening recommendations for, 641*t*
 tissue and urine lab tests for management of, 642–643*t*
- Prostate gland, digital rectal exam of, 638
- Prostate Health Index (PHI), 647
- Prostate-specific antigen (PSA)
 definition and normal range of, 517
 factors and drugs that affect level of, 645, 646*t*
 forms of and normal range, 640
 men (various ages/races) normal range of, 643*t*
 prostate cancer and interpreting level of, 645*b*
 use of as tumor marker, 514, 515*t*
 uses of, 644
 velocity of, 646
- Prostate-specific antigen density (PSAD), 646
- Prostate-specific antigen doubling time (PSADT), definition of, 646
- Prostatitis
 definition, cause, symptoms of, 648
 four-glass method to diagnose chronic, 650
 laboratory tests to diagnose, 435
 NIH categories/types of, 648, 649*t*
- Protease inhibitors (PIs), 101
- Protein
 causes of increased urine, 217*t*
 description and normal range for urine, 214
- Protein binding
 bound and unbound portions of drug, 88–90
 drug concentrations with bound and unbound drug, 81
- Protein C, function and deficiency of, 380, 386
- Protein S, function and deficiency of, 380, 386
- Protein synthesis, liver function test of, 137

- Proteinuria, 60
- Proteome, more complex than genome, 40
- Proteomics
 definition of, 38–40
 personalized medicine and, 19
- Prothrombin time (PT)
 definition and normal range of, 387
 monitors anticoagulation therapy, 385
 normal range and use of, 318
- Proton pump inhibitors (PPIs), 342
- Protozoa, laboratory tests for detecting, 423–427*t*
- PSA. *See* Prostate-specific antigen
- PSAD. *See* Prostate-specific antigen density
- PSADT. *See* Prostate-specific antigen doubling time
- Pseudoheparin resistance, definition of, 390
- Pseudomembranous colitis, causes and diagnosis of, 343–344
- PSM. *See* Patient self-management
- PST. *See* Patient self-testing
- Psychotropic drugs, 85*t*, 107–108
- PT. *See* Prothrombin time
- PT/INR, evaluation of prolonged, 318, 318*f*
- Pteroylglutamic acid. *See* Folic acid
- PTH. *See* Parathyroid hormone
- Public health risk
 CLIA-88 categories of tests based on, 14
 FDA classifies POC tests by, 51
- Public Readiness and Emergency Preparedness Act, 66
- PubMed, indexing and abstracting service, 49
- Pulmonary function test (PFT)
 clinical use of, 302
 evaluation of interstitial lung disease with, 311*b*
 pulmonary diseases and results of, 303*t*
 types and measurements of, 302–313
 uses of, 304*t*
- Pulse polarography, 26
- Pulsed-field electrophoresis (PFGE), components and uses of, 29
- Purified protein derivative (PPD), of tuberculosis, 484
- Pyelonephritis, antibiotic regimen based on laboratory tests to treat, 429*b*
- Q**
- QC. *See* Quality control
- Quadrupole mass spectrometer, 34–35
- Quantitative antinuclear antibody (ANA) assay, definition and immunofluorescent patterns in, 496
- Qualitative test
 definition and examples of, 4, 5
 examples of, 5
 lacks reference range, 5
 positive or negative result from, 5
- Quality control (QC) process, laboratory, 20
- Quantitative antinuclear antibody (ANA) assay, definition and normal range of, 496
- Quantitative assay
 calculation of accuracy in, 3
 definition of, 552
- Quantitative test, definition and examples of, 5
- Quickview chart, contents of typical, 10*f*
- Quinidine, therapeutic range and clinical considerations, 104
- R**
- RA. *See* Rheumatoid arthritis
- Radioactive iodine uptake test, diseases diagnosed with, 185–186
- Radioimmunoassay (RIA)
 history, advantages/disadvantages of, 32, 629
 in vitro drug interference seen with, 44
- RADT. *See* Rapid antigen detection test
- Rapid antigen detection test (RADT), 433
- Rapid plasma reagin (RPR) test, 437
- Rapid urease test, for *H. pylori*, 342–343
- Rate of change, of lab test result and, 15
- RBC. *See* Red blood cell
- RBF. *See* Renal blood flow
- RDW. *See* Red cell distribution width
- Reagent blank, of spectrophotometer, 21
- Real-time reverse transcription polymerase chain reaction (rtRT-PCR), molecular test, 55–56
- Recurrence surveillance, bladder urothelial carcinoma and, 5*b*
- Red blood cell (RBC), 356*t*
- Red blood cell (RBC) count
 definition and normal range of, 357–358
 pediatric and adult normal ranges, 594
- Red blood cell indices
 definition and normal range of, 356*t*, 358
 pediatric and adult normal ranges, 595*t*
- Red cell distribution width (RDW), definition and normal range of, 356*t*, 358–359
- Red man syndrome, vancomycin toxicity, 97
- Redox potential difference, definition, 24
- Redox process, 24
- Reed-Sternberg cell, 374
- Reference electrode, 24
- Reference population, Gaussian (random) value distribution of, 5–6, 6*f*
- Reference range
 also known as *reference interval* or *reference value*, 5
 calculation of, 5
 definition of, 5, 6*f*
 different values for total and free substances, 3
 factors that influence/change, 5–6
- inaccurate if calculated from non-Gaussian test results, 6
 lab test value compared to, 15
 pediatric and geriatric lab test, 11, 12*t*
 preferred over *normal range*, 5
- Reflectance photometry, CLIA-waived POC test for cholesterol using, 59
- Refractometer, measure urine specific gravity, 216
- Refractometry, principles and uses of, 23
- Relative standard deviation, coefficient of variance and, 53
- Renal blood flow (RBF), 202
- Renal dysfunction, lab tests affected by, 13
- Renal function, age-related development of, 588–589
- Renal homeostasis, role of potassium in, 238–239, 239*f*
- Renal plasma flow (RPF), equation for, 202
- Renal system, regulation of acid-base by, 290–291
- Renin-angiotensin-aldosterone system, water/sodium regulation by, 231, 232–233
- Reproductive cycle, anatomy and physiology and phases of, 601
- Reserve volume (RV), definition of lung, 310, 310*f*
- Respiratory acidosis
 causes of, 294, 296*t*
 compensatory response to, 292*t*
- Respiratory alkalosis
 characterized by, 294, 296*t*
 compensatory response to, 292*t*
- Respiratory depression, acid-base disorder with acute, 294*b*
- Respiratory system, regulation of acid-base by, 290
- Reticulocyte count, definition and normal range of, 356*t*, 359
- Reticulocyte index (RI), equation for, 359
- Retinol-binding protein, 277*t*, 279
- Reverse transcriptase polymerase chain reaction (RT-PCR)
 assay, 330
 molecular monitoring with, 521
- Reverse transcription-loop-mediated isothermal amplification (RT-LAMP), 56
- RFs. *See* Rheumatoid factors
- Rheumatic arthritis (RA), nonrheumatic tests for, 503
- Rheumatic disease
 laboratory tests to diagnose and assess, 492–493
 nonrheumatic tests and diseases associated with, 500–501
 presence of antinuclear cytoplasmic antibodies in, 497
 tests to monitor drug therapy for, 506–507, 507–508*t*

- Rheumatoid arthritis (RA)
 ACR/EULAR classification criteria for, 502
 laboratory tests and diagnosis of, 501–503
 presence of rheumatoid factor in, 492
- Rheumatoid factor (RF)
 definition of, 492–493
 JIA and presence of, 504
 quantitative and qualitative assay of, 492–493
 test for rheumatoid arthritis, 502
- RI. *See* Reticulocyte index
- RIA. *See* Radioimmunoassay
- Ribonucleic acid (RNA) test, for hepatitis C virus, 4
- Ribonucleoprotein antibodies (anti-RNP), definition and normal range of, 495
- Rickets, pediatric, 585*b*
- RNA. *See* Ribonucleic acid
- Ro/Sjögren syndrome A antibody (anti-Ro/SSA), test for, 495
- RPF. *See* Renal plasma flow
- RPR. *See* Rapid plasma reagin
- RT-LAMP. *See* Reverse transcription-loop-mediated isothermal amplification
- RT-PCR assay, for *C. difficile* infection, 344
- RT-PCR. *See* Reverse transcriptase polymerase chain reaction
- rtRT-PCR. *See* Real-time reverse transcription polymerase chain reaction
- Rumack-Matthew nomogram, for acetaminophen poisoning, 554
- RV. *See* Reserve volume
- S**
- SABA. *See* Short-acting β_2 -agonists
- Salicylate poisoning, Dome nomogram categories for, 554
- Saliva
 drug toxicity strengths and weaknesses of specimen, 557*t*
 substitute for unbound drug concentration, 90, 94
- SAMHSA. *See* Substance Abuse and Mental Health Services Administration
- Sample timing
 digoxin and importance of, 87, 87*b*
 peak, trough, or “random” drawing, 77, 81–85
- SaO₂. *See* Arterial oxygen saturation
- Sarcopenia
 focus of current malnutrition research, 275
 prevalence in population by age, 276*t*
- SARS-CoV-2. *See* Severe acute respiratory syndrome coronavirus 2
- SBT. *See* Serum bactericidal test
- Schilling test, for vitamin B₁₂, 362
- Schlichter test, 417
- Schwartz bedside equation, for glomerular filtration rate, 590
- Scleroderma, presence of RF in, 492
- SCr. *See* Serum creatinine
- Screening test
 characteristics of, 8
 definition, features, and examples of, 8, 8*t*
- ScvO₂. *See* Central venous oxygen saturation
- SDD. *See* Susceptible-dose dependent
- Secondary medical literature, description of, 49
- SEGA. *See* Subependymal giant cell astrocytoma
- Seizures, hyponatremia and, 579*b*
- Selective serotonin reuptake inhibitors, therapeutic range, 107
- Selenium
 deficiency and excess of, 259
 description, physiology, and normal range of, 258
- Self-monitoring blood glucose (SMBG) monitors, 171
- Self-monitoring tests, blood glucose, 170–171
- Semiquantitative test, definition and examples of, 6
- Sensitivity
 definition of positive percent agreement or, 53
 definition, examples, calculation of, 6, 7*t*
 performance characteristic independent of population tested, 53
 predictive value derived from, 4, 4*t*
- Serological tests, for chronic diseases and public health surveillance, 56
- Serology tests
 to detect antibody response to a virus, 473–474
 to detect fungi, 458
- Serotonin norepinephrine reuptake inhibitors, therapeutic range, 107
- Sertoli cells, in testes, 625, 626
- Serum, definition and components of, 7
- Serum acetaminophen
 overdose and, 554, 555*b*
See also Acetaminophen
- Serum albumin
 correlation with C-reactive protein, 278*f*
 not clinical marker for nutritional status, 277
 pediatric and adult normal ranges, 592
 physiologic functions of, 276–277, 277*t*
See also Albumin
- Serum antinuclear antibody titer, 5
- Serum bactericidal test (SBT, Schlichter’s test), description of, 417
- Serum bicarbonate
 pediatric and adult normal ranges, 582
 total CO₂ content and, 288
- venous total carbon dioxide and, 289
See also Bicarbonate
- Serum binding, altered drug, 88
- Serum calcium
 also known as ionized calcium, 3
 causes of abnormal concentration of, 249
See also Calcium
- Serum concentrations, objectives and types of analysis for toxin, 552–553
- Serum creatinine (SCr)
 description and normal range for, 203
 factors that influence pediatric, 587
 Jaffe method and IDMS method to measure, 587
 kidney function and, 202
 laboratory methods to measure, 203
 pediatric and adult normal ranges, 587
See also Creatinine
- Serum Cystatin C, glomerular filtration rate estimated from, 591–592
- Serum digoxin concentration, toxicity and, 555
- Serum drug concentrations, therapeutic effect or toxicity predicted by, 75
- Serum ferritin, definition and normal range of, 365
- Serum iron, definition and normal range of, 365
- Serum lactate, definition and normal range of, 289
- Serum osmolality (mOsm)
 formula for, 174
 normal range and equation for, 229–230
- Serum potassium
 Gaussian (random) value distribution of, 6*f*
See also Potassium
- Serum prealbumin, functions of, 278
- Serum protein electrophoresis (SPE)
 drugs that affect, 13
 uses of, 26
- Serum retinol-binding protein, not clinical marker for nutritional status, 279
- Serum sodium
 description and normal range for urine, 219–220
 description and physiology of, 229
 pediatric and adult normal ranges, 578
See also Sodium
- Serum testosterone
 erectile dysfunction and low, 630*b*
 guidelines for treatment of low, 629
See also Testosterone
- Serum transferrin, function of, 279
- Serum uric acid, definition and normal range of, 508
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), CLIA-waived POC tests for, 55

- Sex hormone-binding globulin (SHBG), 611, 625–626, 626*t*
- Sexual Health Inventory for Men (SHIM), questionnaire, 634, 634*t*
- Sexually transmitted diseases (STDs), laboratory tests to diagnose, 435–438
- SHBG. *See* Sex hormone-binding globulin
- Sheiner equation, normalize measure total concentration, 89
- SHIM. *See* Sexual Health Inventory for Men
- Short-acting β_2 -agonists (SABA), 307
- Shortness of breath, acid-base disorder with fever and, 295*b*
- SI. *See* International Systems of Units
- SIADH. *See* Syndrome of inappropriate antidiuretic hormone
- Sickle cell, screening test for, 8
- Sickle cell disease, hemoglobin
CLIA-waived POC test, 58
- Sickle cell trait, 368
- SID. *See* Strong ion difference
- Side-scattered light (SSC), 36
- SIHD. *See* Stable ischemic heart disease
- Single nucleotide polymorphism (SNP)
definition of, 120*t*
NCBI numbers for, 124
- Single-stranded DNA antibodies, definition of, 495
- Singlet state, 22
- SIRS. *See* Systemic inflammatory response syndrome
- Six-minute walk test (6MWT), purpose of, 312, 308–309*b*
- Sjögren syndrome, presence of RF and ANA in, 495, 492
- SLCO1B1*. *See* Solute carrier organic anion transporter family member 1B1
- SLE. *See* Systemic lupus erythematosus
- Slow vital capacity (SVC), definition of lung, 303, 310
- SMBG. *See* Self-monitoring blood glucose
- Smith antibodies (anti-Sm),
definition of, 495
- SNP. *See* Single nucleotide polymorphism
- Sodium
description and normal range for urine, 219–220
description and physiology of, 229
pediatric and adult normal ranges, 578
See also Serum sodium
- Solid-phase technology, CLIA-waived POC test for cholesterol using, 59
- Solid-state electrodes, 24
- Solute carrier organic anion transporter family member 1B1 (*SLCO1B1*), 126–127
- Somatic mutations, definition of, 129
- Somatic variant, definition of, 120*t*
- Southern blot electrophoresis, methods and use for, 27
- SPE. *See* Serum protein electrophoresis
- Specific gravity, description and normal range for urine, 216
- Specificity
definition of negative percent agreement or, 53
definition, examples, calculation of, 7, 7*t*
performance characteristic independent of population tested, 53
predictive value derived from 4, 4*t*
quantitative laboratory tests and definition of, 7
- Specimens
CLIA-waived POC tests and common types of, 54
CLIA-waived POC tests require unprocessed, 54
definition and types of, 7
inaccurate laboratory test result due to, 9
- Specimen collection and timing, manufacturer's guidelines for CLIA-waived POC test, 55
- Specimen collection techniques, before offering CLIA-waived POC tests, 68
- Spectrophotometers
molecular absorption, 21–22
types and components of, 21–23, 21*f*
- Spectrophotometric method, CLIA-waived POC test for hemoglobin using, 58
- SPICE bacteria (mnemonic for specific genus and species gram-negative bacteria), 418
- Spirochetes, laboratory tests for detecting, 422*t*, 425*t*
- Spirometry
ATS and ERS standards for, 307
definition and use of, 302, 304
procedure for, 305, 307
standardization of measurements for, 305
- SpO₂, lowest arterial oxygen saturation, 312
- Sports, drug testing in, 557–558
- Spurious laboratory test value, definition of, 16
- Sputum smear, timing of laboratory sample for, 11
- SSC. *See* Side-scattered light
- Stable ischemic heart disease (SIHD), 140
- Stable isotope dilution liquid chromatography, 629
- Standard deviation, precision of quantitative CLIA-waived POC tests by, 53
- Standard error of mean, precision of quantitative CLIA-waived POC tests by, 53
- Star allele, definition of, 120*t*
- STD. *See* Sexually transmitted disease
- Steady state
definition of, 81
drug half-life can predict time to, 85
not reached faster with loading dose, 86
- Steady-state average concentration,
definition of, 86–87
- Steady-state maximum concentration,
definition of, 86
- Steady-state minimum concentration,
definition of, 86
- STEMI. *See* ST-segment elevation myocardial infarction
- Stewart approach, acid-base and, 290
- Stokes shift, definition of, 22, 36
- Streptococcal pharyngitis, laboratory tests to diagnose, 433
- Stroke volume (SV), definition of cardiac, 140
- Strong ion, definition of, 290
- Strong ion difference (SID), 290
- ST-segment elevation myocardial infarction (STEMI), 140
- Subependymal giant cell astrocytoma (SEGA), drugs for, 106
- Subjective Global Assessment, of nutrition, 281
- Substance Abuse and Mental Health Services Administration (SAMHSA)
drug testing rules from, 544, 547
cutoff drug concentrations for urine drug tests, 546*t*
website poisoning information, 559
- Substance use disorders, symptoms of, 558–559
- SULT1A1* gene, 389
- Surveillance susceptibility testing, definition and use of, 431
- Susceptibility testing
for anaerobic or fastidious bacteria, 420
methods for reporting results of, 421, 427–431
- Susceptible-dose dependent (SDD), CLSI interpretive criterion for bacteria, 412
- SV. *See* Stroke volume
- SVC. *See* Slow vital capacity
- SvO₂. *See* Venous oxygen saturation
- Sweat, drug toxicity strengths and weakness of specimen, 557*t*
- Syndrome of inappropriate antidiuretic hormone (SIADH), causes of, 232, 235*f*
- Syndromic panels, 38
- Synergy testing, antimicrobial combination and definition of, 417–418
- Synovial fluid
analysis for rheumatoid arthritis and, 503
arthrocentesis, characteristics, and assessment of, 499, 500*t*, 500*b*
interpretation of findings of, 439*t*
JIA and analysis of, 505
- Syphilis, symptoms, stages, and laboratory tests to diagnose, 436–437
- Systemic inflammatory response syndrome (SIRS), 333, 339

- Systemic lupus erythematosus (SLE)
 EULAR/ACR classification of, 505
 laboratory tests for, 494–496, 505
 nonrheumatic tests for, 506
 presence of ANA and RF in, 492
- Systolic heart failure, definition of, 142
- T**
- T lymphocytes, types and functions of, 370
- T₃. *See* Triiodothyronine
- T₃ resin uptake, laboratory test for thyroid disease, 181–182
- T₄. *See* Thyroxine
- Tandem mass spectrometer, use of, 35
- Targeted therapy, resistance to, 131
- TAT. *See* Turnaround time
- TB. *See* Tuberculosis
- TBG. *See* Thyroxine-binding globulin
- TBW. *See* Total body water; Total body weight
- TC. *See* Total cholesterol
- TCA. *See* Tricyclic antidepressants
- Tertiary medical literature, description and examples of, 47, 48*b*
- Tests. *See* Laboratory tests. *See also* Specific names of tests
- Testosterone
 drugs affecting lab value of, 606*t*
 laboratory methods to determine level of, 629
 pediatric and adult normal ranges, 604–605
 physiologic effect of, 626*t*
 production and effects of, 625
See also Bioavailable testosterone; Free testosterone; Serum testosterone; Total testosterone
- Tetany, symptom of hypocalcemia, 250
- TFPI. *See* Tissue factor pathway inhibitor
- TG. *See* Triglycerides
- Thalassemia, 368
- THC. *See* Total hemolytic complement
- Therapeutic drug monitoring
 characteristics of ideal drugs for, 76
 definition of, 75
 use of total drug concentration (unbound and bound), 88–89
- Therapeutic range
 age-related changes affect, 81
 definition and other names for, 77
 how determined for older antiepileptic drugs, 79
 pharmacodynamics of drug affect, 79
 population-based average for, 77, 80*f*
- Thin layer chromatography (TLC), components and use of, 29
- Thiopurine methyltransferase (TPMT), phenotype, 127*b*, 128
- Third International Consensus Definition for Sepsis and Septic Shock (Sepsis-3), 289
- Three-dimensional test, 418
- Threshold value, sensitivity of quantitative test and cutoff value or, 53
- Thromboxane A₂, platelet aggregation and, 378
- Thrombin time (TT), definition, use, and normal range of, 392
- Thrombocytopenia, definition and causes of, 382
- Thrombocytopenia, definition and causes of, 382, 382*t*
- Thrombocytosis, definition and causes of, 382
- Thromboplastin, ISI versus INR lab results for, 9
- Thrombotic disorders, tests to diagnose, 386
- Thrombus, processes involved in formation of arterial, 378
- Thyroid disease, laboratory tests for, 178–181
- Thyroid disorders, 151, 178
- Thyroid function tests (TFTs)
 categories of, 178–181
 drugs that affect, 13, 185
- Thyroid gland, anatomy and physiology of, 177
- Thyroid-binding protein, factors/diseases that increase/decrease, 181*t*
- Thyroid hormone-binding ratio, 182
- Thyroid-stimulating hormone (TSH)
 function of, 177
 subunits of, 183–184
 thyroid and nonthyroid disease levels of, 180*t*
- Thyrotoxicosis, cause and symptoms of, 178
- Thyrotropin, 177
- Thyrotropin-releasing hormone (TRH), function of, 177
- Thyroxine (T₄), function of thyroid hormone, 177
- Thyroxine-binding globulin (TBG), 177
- TIBC. *See* Total iron-binding capacity
- Tidal volume (TV), definition of, 310, 310*f*
- Time of sample draw, versus phlebotomist's time of intended draw, 77
- Time-kill studies, description of, 417
- Timing
 considerations for accurate sample, 82
 frequent source of error from sample collection, 81
 misleading results from incorrect laboratory test, 9
- Tissue factor pathway inhibitor (TFPI), 379
- TLA. *See* Total laboratory automation
- TLC. *See* Thin layer chromatography
- TMB. *See* Tumor mutation burden
- TN. *See* True negative
- Total bilirubin
 normal range of, 321
 pediatric and adult normal ranges, 593
See also Bilirubin
- Total body water (TBW), pediatric versus adult, 576–577
- Total body weight (TBW), creatinine clearance and, 206
- Total carbon dioxide, equivalent to serum bicarbonate, 229
- Total cholesterol (TC)
 exogenous and synthesized sources of, 149, 150*f*
 function of, 149
 Healthy People 2020, goal for, 149
 lipid panel component and values for, 154
- Total CO₂ content, serum bicarbonate and, 288, 289
- Total hemolytic complement (THC), definition and normal range of, 498
- Total iron-binding capacity (TIBC), definition and normal range of, 365
- Total laboratory automation (TLA), goal, scope, and motivation for, 20
- Total lung capacity (TLC), tests included in, 310, 310*f*
- Total serum T₃, laboratory test for thyroid disease, 183
- Total serum T₄, laboratory test for thyroid disease, 179–180
- Total testosterone
 causes of increased, 629
 pediatric and adult normal ranges, 628
- Tourniquet time, hemoconcentrate analytes changed by prolonged, 9
- Toxicity, serum contractions guide therapies to treat, 553*t*
- Toxicokinetics, definition of, 556
- Toxicological analysis, characteristics of specimens for, 557*t*
- Toxicology, postmortem, 556
- Toxicology hold, definition of, 556
- Toxicology screen (tox screen), urine drug test as, 544
- Tozer equation, 89–90
- TP. *See* True positive
- Trace elements, descriptions and functions of, 254–260
- Transcription mediated amplification, 38
- Transferrin iron saturation, 332
- Transrectal ultrasound of the prostate (TRUS), 638, 639
- Transtubular potassium gradient (TTKG), 220
- Treponema pallidum*, syphilis caused by, 436
- TRH. *See* Thyrotropin-releasing hormone
- Trichomonas, laboratory tests to diagnose, 437–438
- Tricyclic antidepressants (TCAs), therapeutic range and clinical considerations, 107

- Triglycerides (TG)
 effects of diet, exercise, and drugs on, 149
 exogenous and synthesized sources of, 149, 150*f*
 function of, 149
 lipid panel component and values for, 154–155
 pregnancy affects, 13
- Triiodothyronine (T₃), function of thyroid hormone, 177
- Triplet state, 22
- Troponins
 causes for elevated, 141*t*
 high-sensitivity, 141
 timing of postmyocardial infarction level of, 11
- Trough, definition and reasons to use, 86
- Trousseau sign, hypocalcemia and, 250
- True negative (TN), 3, 4*t*
- True positive (TP), 3, 4*t*
- TRUS. *See* Transrectal ultrasound of the prostate
- TSH. *See* Thyroid-stimulating hormone
- TST. *See* Tuberculin skin test
- TTKG. *See* Transtubular potassium gradient
- Tuberculin skin test (TST), for tuberculosis, 8, 484–485
- Tuberculosis, antimycobacterial four-drug regimen for, 100
- Tumor cells, array-based comparative hybridization profiling of, 40
- Tumor marker
 clinical use of different, 515–516*t*
 definition, categories, and uses of, 513
 personalized treatment of cancer with different, 516*t*
 type of biomarker, 4
- Tumor marker tests
 accessibility and cost-effectiveness of, 514–515
 sensitivity and specificity of, 514
- Tumor molecular testing, oncology guided by, 130
- Tumor mutation burden (TMB), definition of, 523
- Turbidimetry, definition, uses, advantages/disadvantages of, 23
- Turn-around time (TAT)
 CLIA-waived POCT test has quick, 54–55
 POC testing and decreased, 14
- TV. *See* Tidal volume
- Type 1 and type 2 diabetes mellitus. *See* Diabetes mellitus
- U**
- U.S. Department of Health and Human Services, Medicare costs and, 20
- U.S. Drug Enforcement Administration (DEA), website poisoning information, 559
- U.S. Food and Drug Administration (FDA). *See* FDA
- Ubiquitous Pharmacogenomics Consortium (U-PGx), pre-emptive genotyping by, 123
- UCr. *See* Urine creatinine
- UFC. *See* Urine-free cortisol
- UFH. *See* Unfractionated heparin
- Ulcer disease, description, cause, and tests for, 342–343
- ULN. *See* Upper limit of normal
- Ultradian rhythm, description of, 12
- Unbound drug, measurement of, 89
- Unfractionated heparin (UFH), 380
- Units, laboratory test results and types of, 7
- U-PGx. *See* Ubiquitous Pharmacogenomics Consortium
- UPOINT, classification for symptoms of chronic pelvic pain, 649
- Upper limit of normal (ULN), lab test result of, 15
- Upper respiratory tract, types of specimens for CLIA-waived POC test of, 55
- Urea breath test, for *H. pylori*, 342
- Uridine diphosphate glucuronosyltransferase (UGTIA), elimination of bilirubin by, 128
- Uridine-rich ribonucleoprotein antibodies (anti-U₁RNP), definition and normal range of, 495
- Urinalysis
 identifying candidates for CLIA-waived POC, 60
 macroscopic and microscopic and uses of, 208, 212–214
 pharmacist monitors diabetes with CLIA-waived POC, 59
 types of CLIA-waived POC tests for, 59
- Urinary tract infection (UTI)
 bacteriuria and, 213
 laboratory tests to diagnose, 434–435
- Urinary urea nitrogen (UUN), 280
- Urine
 causes of coloration of, 212*t*
 dipstick or tablet reagent for CLIA-waived POC test of, 54
 toxicological strengths and weaknesses of specimen, 557*t*
- Urine creatinine (UCr), kidney function and, 202
- Urine dipstick, CLIA-waived POC urinalysis by, 59
- Urine drug screen
 list of immunoassays for doing, 544
 preliminary, stat, or provisional, 544
 qualitative result from, 544
 reasons for, 546
 substances and rate of workforce positive, 545*t*
 substances interfering with immunoassay, 550*t*
- Urine-free cortisol (UFC), test for Cushing syndrome, 187–188
- Urine glucose, diabetes and, 170
- Urine specimen, intentional or unintentional altering of, 549
- Urine uric acid concentration, definition and normal range of, 509–510
- Urinometer, measure urine specific gravity, 216
- Urobilinogen, description and normal range for urine, 217
- Uroflowmetry testing, limitation of, 638
- Uterine outflow obstruction, definition and causes of, 607
- UTI. *See* Urinary tract infection
- UUN. *See* Urinary urea nitrogen
- V**
- V:Q ratio. *See* Ventilation: perfusion ratio
- Validity, use of accuracy/bias/precision to evaluate CLIA-waived POC test, 53
- Vancomycin, toxicities associated with, 97
- Vancomycin intermediate *Staphylococcus aureus* (VISA), tests to detect, 97, 420
- Vancomycin-resistant enterococci (VRE), tests to detect, 420
- Vancomycin-resistant *Staphylococcus aureus* (VRSA), tests to detect, 420
- VAP. *See* Ventilator-associated pneumonia
- Vapor pressure osmometry, 23
- Vasculitis, patterns of ANCA in, 496
- Vasopressin, water/sodium regulation by, 231, 232
- VDRL. *See* Venereal Disease Research Laboratory
- Venereal Disease Research Laboratory (VDRL), 5, 437
- Venous oxygen saturation (SvO₂)
 definition and normal range, 289–290
 taken from pulmonary artery catheter, 289–290
- Venous thromboembolism (VTE), Wells or Geneva score for probability of, 386, 386*b*, 393
- Venous total carbon dioxide, definition and normal range of, 289
- Ventilation (V), definition of, 301–302
- Ventilation: perfusion ratio (V:Q), ways to normalize, 302
- Ventilator-associated pneumonia (VAP), 433
- Verigene Gram-Positive Bloodstream Infection Test, 408
- Very low-density lipoproteins (VLDLs), function and characteristics of, 150, 150*f*, 151*t*
- Viral hepatitis, types of, 326
- Viral load, CLIA-waived POC tests for influenza A and B depend on, 63
- Virilization, definition, causes, and symptoms of, 611, 613*t*

- Viruses
description and classification of, 461
laboratory tests for medically important DNA, 463–465*t*
laboratory tests for medically important RNA, 466–470*t*
laboratory tests to identify, 461–462, 471–474
- VISA. *See* Vancomycin intermediate *Staphylococcus aureus*
- Visceral proteins, definition, types of, physiologic function of, 276, 277*t*
- Vitamin B₁₂ (cobalamin)
anemia and symptoms from, 361, 361*t*, 362
sources and absorption of, 362
- Vitamin D, cause of deficiency in pediatrics, 584
- Vitamin K, definition and reasons for low level of, 318
- Vitamin K epoxide reductase (VKOR), definition and use of, 388
- VKOR. *See* Vitamin K epoxide reductase
- VLDLs. *See* Very low-density lipoproteins
- Voltammetry, description, components, types of, 25–26
- Volume-time curve, spirometry and, 302, 304*f*
- von Willebrand disease, 386
- von Willebrand disease, coagulation test for, 381*t*
- von Willebrand factor (vWF), 378
- VRE. *See* Vancomycin-resistant enterococci
- VRSA. *See* Vancomycin-resistant *Staphylococcus aureus*
- VTE. *See* Venous thromboembolism
- vWF. *See* von Willebrand factor
- W**
- Waived laboratories, definition of, 52
- Waived point-of-care tests, definition of, 51
- Waived test status, definition of, 14
- Warfarin
factors that influence dose and pharmacokinetics of, 388, 389*t*
tests to monitor therapy with, 388
- Warfarin pharmacogenetics, 129–130
- Water deprivation test, diabetes insipidus and, 189–190, 189*t*
- Wavelength of light, measured in nanometers (nm), 21
- WBC. *See* White blood cell
- Weak ions, definition of, 290
- Wellness, patient-centered care and pharmacist focus on, 51
- Wells score, probability of venous thromboembolism, 393
- Western blot electrophoresis, with ELISA to confirm HIV, 27, 28*f*
- White blood cell (WBC), 356*t*
- White blood cell (WBC) count
classification, function, and normal range of, 368, 369*t*
definition and normal range of, 358 and differential (types of), 368
pediatric and adult normal ranges, 596, 596*t*
- White blood cell (WBC), disorders, 371*t*
- WHO. *See* World Health Organization
- Whole blood, finger stick specimen for CLIA-waived POC test of, 54
- Wilson disease, genetic copper deficiency, 255–256
- Winter-Tozer equation, normalize phenytoin concentration, 94
- Workplace drug screening, interpretation of, 551*b*
- World Health Organization (WHO), G6PD phenotyping from, 128
- XYZ**
- xPOCT. *See* Multiplexed point-of-care testing
- Yeasts, genus and species names of medically important, 446*t*
- Zinc, description, physiology, normal range of, 256
- Zinc trafficking, definition of, 256
- Zone of inhibition, CLSI interpretive criteria for diameter of, 416
- Z-potential, definition of, 32

